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ABSTRACT 
 
Human Immunodeficiency Virus type 1 (HIV-1) targets immune cells, including 
CD4+ T cells, macrophages, and dendritic cells (DC). Macrophages are critically 
important for their contributions to viral propagation and inflammation in vivo during 
infection, though the current understanding of host-pathogen interactions in this cell type 
remains deeply inadequate. A better understanding of how HIV-1 infects macrophages 
despite facing numerous cellular defenses may inform therapeutic approaches aimed at 
preventing HIV-1 infection and its sequelae. A major component of the anti-HIV-1 
defense is SAM domain and HD domain-containing protein 1 (SAMHD1), a 
phosphohydrolase responsible for restricting the generation of double-stranded viral 
DNA (dsDNA) from a single-stranded RNA (ssRNA) genome. It functions by converting 
deoxynucleoside triphosphates (dNTP) to deoxynucleosides (dN) in noncycling cells, a 
process dependent on tetramerization that is inhibited through threonine-592 (T592) 
phoshphorylation. We discovered that SAMHD1 activity is a critical determinant of HIV-
1 infection in macrophages, and that despite its abundant expression, can exist in an 
inactive state (phosphor-T592) allowing macrophages to be highly susceptible to HIV-1. 
We found that biological sex is a major determinant of macrophage infectivity with HIV-  
1, and that the relative susceptibility of male- versus female-derived macrophages hinges 
exclusively on SAMHD1 activity. Furthermore, we have established SAMHD1 as the 
principal effector through which diverse interferons (IFN) act in macrophages, and that 
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activation of SAMHD1 through IFN signaling establishes a state of HIV-1 resistance. We 
find that cyclin-dependent kinase 1 (CDK1) is the major determinant of IFN-induced 
SAMHD1 activation, and that depletion of CDK1 through siRNA alone drives SAMHD1 
activation in MDM. Interestingly, a variety of FDA-approved tyrosine kinase inhibitors 
(TKI) phenocopy the effects of IFNs, and their activity depends on their ability to 
activate SAMHD1. Furthermore, we find that macrophage infection with HIV-1 induces 
a similar state of protection from subsequent challenge, which correlates with activation 
of SAMHD1. Interestingly, this protection does not appear to involve the production of 
IFNs. Using phosphoproteomic and RNA-sequencing approaches, we have begun to 
unravel the pathways responsible for SAMHD1 activation resulting from HIV-1 sensing, 
IFN stimulation, and the use of TKIs, which exhibit overlapping but distinct mechanisms 
of action.  
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Human immunodeficiency virus type 1: past and present  
 Acquired immunodeficiency syndrome (AIDS) was first recognized in patients in 
the United States as early as 1981, under the guise of patients infected with a rare 
pneumonia caused by Pneumocystis carinii or those presenting with a rare form of 
cancer, Kaposi’s Sarcoma [1]. The appearance of AIDS was inopportune: the advent of 
effective antimicrobials precipitated a general sense of complacency toward infectious 
microbes, and many believed that the war on microorganisms such as bacteria, fungi, and 
viruses had been won. A prevailing sense that microbes, at least in industrialized 
countries, no longer posed a threat to humanity, hung over science and medicine [2, 3]. 
Retroviruses themselves were not believed to cause disease in humans, as efforts to find 
retroviruses, much less attribute them to diseases had proved fruitless. The blossoming 
field of retrovirology as we know it today withered while a global pandemic loomed [4].  
It had been long hypothesized that certain viruses had the ability to cause tumors, 
termed oncogenic viruses. However little data to support the existence of human 
oncogenic retroviruses was available until the early 1980s [5]. A few laboratories 
persisted in their efforts to characterize these esoteric pathogens, namely those of Howard 
Temin and David Baltimore. The stage was set in 1970 with the co-discovery of reverse 
transcriptase (RT) as a component of Rous Sarcoma Virus (RSV) by Temin and 
Baltimore [6-8], who had been tenacious advocates for the existence of oncogenic 
viruses. This breakthrough, profound in its challenge of the ‘central dogma’, set the stage 
for the discovery of the first leukemogenic virus, human T-cell leukemia virus types 1 
and 2 (HTLV-1 and HTLV-2) [5, 9]. By 1979, it was clear that viruses were not only 
capable of causing human cancers, but that they possessed the ability to pass genetic 
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information from RNA to DNA. It would not be long before the AIDS epidemic made 
landfall, and while the causative agent remained elusive, these discoveries laid the critical 
groundwork for the breakthrough discovery of HIV [10, 11].  
By the mid-1980s, AIDS was widely recognized as a persistent disease with a 
significant period of clinical dormancy from exposure to immunosuppression. However 
few clues existed regarding potential causes of AIDS[10, 12]. One common and major 
theme permeated AIDS cases: patients experiencing profound immunosuppression shared 
a precipitous decline in CD4+ T cell counts [13-15]. HTLV immediately emerged as a 
prime suspect. It was known that HTLV was transmitted through blood and sexual 
activity, and it had been previously shown that lymphotropic viruses were capable of 
causing AIDS-like syndromes in various animal models [5, 9]. The theory that a 
retrovirus was responsible for AIDS proved correct, but not until 1983 would it be 
recognized that a new virus, distinct from HTLV, was responsible for AIDS [11, 16].  
Characterization of that virus followed, and by 1984 it was clear that this newly 
discovered pathogen was indeed a lentiretrovirus, and was initially characterized as 
lymphadenopathy-associated virus (LAV) or HTLV-III [17, 18]. In May 1986, the virus 
was reclassified as Human Immunodeficiency Virus (HIV). Isolation of another strain in 
West Africa, HIV-2, from patients exhibiting similar symptoms to patients in the United 
States supported a causal relationship between these viruses and AIDS-defining illnesses 
[5]. The establishment of the HIV-AIDS relationship paved the way for novel therapies, 
mainly those that target enzymes required for viral replication, including viral reverse 
transcriptase and integrase [19, 20]. As HIV therapies became mainstream and proved 
efficacious at preventing virus transmission and blunting AIDS-defining illness, a new 
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era was entered in the fight against HIV. By 1995, patients receiving highly active 
antiretroviral therapy (now termed combined antiretroviral therapy, HAART or cART) 
were experiencing what many hoped might be a cure [21].  
The current state of the HIV-1 pandemic is one of both promise and uncertainty. 
The hope for a cure, spurred on by highly effective ART that both brought virus to 
undetectable levels in patients infected with HIV-1, proved premature. Indeed, patients 
living with HIV-1 experience CD4+ T cell rebound and return to near-normal health 
following ART. However cessation of therapy has been demonstrated to result in viral 
rebound and subsequent disease [21-24]. The viral sanctuary, termed the latent HIV-1 
reservoir, had been identified in long-lived memory CD4+ T cells [25]. This reservoir is 
the single greatest barrier to achieving HIV-1 cure, and is responsible for the requirement 
of life-long ART. Strategies aimed at achieving so-called latency ‘reversal’, as well as 
identification of other potential cells or tissue sites responsible for harboring latent HIV-1 
constitute the current state of cure efforts [26, 27].  
 
Immune cells and HIV-1 infection 
 HIV-1 exhibits tropism for three major immune cell types: CD4+ T cells, 
macrophages, and dendritic cells [28]. A hallmark of HIV-1 infection and progression to 
AIDS is the depletion of T lymphocytes, and it is well understood that progressive loss of 
CD4+ T cells is responsible for the vast majority of immunodeficiency associated with 
untreated HIV-1 infection [15]. Although myeloid cells are bona fide targets for HIV-1 
infection, their role in mediating immunodeficiency and progression to AIDS is not well 
understood [28]. Indeed, macrophages can support HIV-1 infection and persistence in the 
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complete absence of CD4+ T cells despite long-term ART, a finding that indicates 
myeloid cells are an important source of virus replication and contribute functionally to 
the latent reservoir [29, 30]. Though some evidence exists to support a role for these cells 
in HIV-1 persistence during therapy, whether these cells harbor truly latent provirus 
remains an important question in the field [31]. Nevertheless, myeloid cells constitute an 
important and arguably neglected area of research in the field of HIV-1.  
 
Macrophages as key players in HIV-1 pathogenesis 
 Macrophages are present in a variety of tissue sites, and their capacity for 
infection with HIV-1 poses a number of distinct clinical problems. Perivascular 
macrophages and microglia, present in the brain, are considered major drivers of an 
important clinical phenomenon known as HIV associated neurocognitive disease 
(HAND) [32-34]. HAND affects HIV-1-infected individuals in the presence or absence 
of ART, though the effects are strongly attenuated when viral suppression is achieved 
[34]. Two major mechanisms for HAND have been proposed: either low-level, ongoing 
virus replication in sanctuary tissue sites or, alternatively, viral products carried over 
from untreated HIV-1 infection perpetuate a state of chronic inflammation involving 
immune cells as well as astrocytes [33]. While virus sequences isolated from the cerebral 
spinal fluid (CNS) of ART-suppressed patients has been shown to exhibit macrophage 
tropism, it is still unknown whether these cells represent a functional HIV-1 reservoir 
[35].  In either case, infection of macrophages and macrophage-like cells is the 
predominant theory regarding HAND etiology, and these cells are likely to play a 
significant role in the systemic inflammation observed in chronically-infected patients.  
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SAMHD1: at the nexus of cell cycle control and virus restriction 
 Macrophages represent a major cellular target for HIV-1 that, unlike activated 
CD4+ T cells, are postmitotic and present unique barriers to infection that distinguish 
them from lymphocytes [36, 37]. For example, macrophages express low levels of the 
HIV-1 receptor and co-receptor, CD4 and CCR5, predisposing them to low rates of 
infectivity when compared to CD4+ T cells [38]. Furthermore, the nature of mature 
macrophages as terminally differentiated cells presents a major barrier to infection once a 
virus has entered the cell. Because macrophages are nondividing, they maintain limiting 
concentrations of dNTPs which are required for cellular DNA replication but are also 
necessary for generation of dsDNA from the ssRNA HIV-1 genome [39]. The 
mechanisms governing dNTP homeostasis are well known, and in many nondividing 
cells this process is controlled through the cellular protein SAM domain and HD domain-
containing protein 1 [40]. SAMHD1 is a triphosphohydrolase that limits dNTP pools by 
catalyzing their conversion to inorganic phosphates and deoxynucleosides (dN) [41]. 
SAMHD1 is highly expressed in macrophages and other myeloid-lineage cells, and its 
ability to restrict both cell division and virus infection hinges on its capacity for dNTP 
hydrolysis [40]. It is a notable driver of autoimmune diseases, including systemic lupus 
erythematosus and Aicardi-Goutieres syndrome, known generally as interferonopathies 
due to a characteristic overproduction of interferons and subsequent chronic 
inflammation [42-44].  
 The ability of SAMHD1 to restrict HIV-1 replication is largely dependent on two 
major checkpoints: it is controlled at both the level of transcription and at the level of 
phosphorylation. In dividing cells such as activated CD4+ T cells, SAMHD1 expression 
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is low and remains largely in a hyperphosphorylated, inactive state [45, 46]. In stark 
contrast to CD4+ T cells, macrophages and other nondividing immune cells express high 
levels of SAMHD1 that remains in a hypophosphorylated, active state [45, 47]. 
Unsurprisingly, SAMHD1 phosphorylation is controlled by a family of cyclin-dependent 
kinases (CDK), which in response to mitogenic stimuli, quickly phosphorylate and 
inactivate its catalytic activity [48]. Thus, cells expressing SAMHD1 can rapidly 
modulate its activity to suit the dNTP requirements of the cell. This is abundantly clear in 
CD4+ T cells, which rapidly phosphorylate SAMHD1 in response to CD3/CD28 
stimulation. Thus, SAMHD1 is not considered a major barrier to infection in cycling cells 
expressing an abundance of CDKs that are known to act on SAMHD1 [45-47]. 
 The nature of SAMHD1 in macrophages and the ability of its activity to be 
modulated has been the subject of recent intense inquiry. We have recently shown that 
the ability of macrophages to be infected by HIV-1 can be predicted by the degree of 
SAMHD1 present in its inactive, phosphorylated state, as outline in Chapter 2 and 
Chapter 3. While macrophages largely resist infection with HIV-1 due to the expression 
of SAMHD1, enzymatic activity appears to be governed by a number of CDKs, which 
are in turn controlled by cell signaling pathways that can be targeted through kinase 
inhibition. The precise pathways responsible for modulation of SAMHD1 activity in 
macrophages remains unknown, and whether phosphatases are key to the rapid induction 
of SAMHD1 activity remains to be elucidated. Further studies aimed at delineating the 
relevant pathways may provide insight not only into HIV-1 restriction, but may also 




The work included in this dissertation uncovers a role for SAMHD1 in response to 
numerous stimuli, and investigates this host restriction factor as the major modulator of 
infection in macrophages. Utilizing primary human monocyte derived macrophages 
(MDM), we have demonstrated that the major antiviral activity of various IFNs hinges on 
their ability to activate SAMHD1, and that IFNs act largely through the induction of CDK1. 
We show that pharmacologic manipulation of SAMHD1 by FDA-approved tyrosine kinase 
inhibitors (TKI) can induce a state of potent HIV-1 restriction in macrophages that is 
strictly dependent SAMHD1 activation. Furthermore, we have demonstrated sex bias in 
HIV-1 infection of MDM, and have described SAMHD1 as a novel regulator of sex-based 
immune differences. Work aimed at elucidating the precise signaling events that lead to 
changes in SAMHD1 activity is ongoing, as are further studies characterizing how 
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While it is known that host sex affects HIV-1 viremia and influences the severity 
of HIV-1 associated neurocognitive disease, a cellular or molecular basis for these 
findings remains elusive. Macrophages are major targets for HIV-1 and contribute to 
viral propagation in vivo.  In the present study, we aimed to address whether sex affects 
HIV-1 infectivity of primary human macrophages and CD4+ T cells in vitro. We find that 
donor sex influences infectivity of monocyte-derived macrophages: macrophages derived 
from healthy female donors were less susceptible to HIV-1 infection than those derived 
from healthy males. This sex-dependent difference was independent of viral entry, 
originated prior to viral integration, and was not observed when in CD4+ T cells from the 
same donors. We report that differential regulation of the host restriction factor 
SAMHD1 is the main factor governing the sex-dependent difference in infectivity. The 
sex-dependent differences in SAMHD1-mediated viral restriction were abolished by 
Vpx-mediated depletion of SAMHD1 or by addition of exogenous deoxynucleosides. We 
conclude that SAMHD1 is an essential modulator of infectivity in a sex-dependent 
manner in macrophages but not in CD4+ T cells, and constitutes a novel component of 
sex-dependent differences in innate immune control of viral infection. 
 
Introduction 
 Sex is an important biological variable with regard to susceptibility and natural 
history of many diseases including HIV-1, though the cellular and molecular basis of 
these observations remains largely unclear. Women constitute the majority of adults 
living with HIV-1, with an estimated 17.8 million women infected, compared to 16.7 
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million men worldwide according to the 2016 UNAIDS data. However, participants in 
clinical research exploring HIV-1 pathogenesis and management overwhelmingly skew 
male. Under-representation of female participants in HIV-1 research, paired with the 
implicit assumption that observations gleaned from overwhelmingly male study 
populations can be extrapolated to females, potentially compromises both the basic and 
clinical understanding of the HIV-1 epidemic. 
 Sex differences in acute HIV-1 infection, progression to acquired 
immunodeficiency syndrome (AIDS), and development of HIV-associated 
neurocognitive disease (HAND) have been examined. Cross-sectional and longitudinal 
cohort studies have described sex differences in plasma viral loads and CD4+ T cell 
counts among new seroconverters and those with chronic HIV-1 infection alike [1-4]. 
Indeed, multiple lines of evidence have shown that HIV-1-infected women maintain 
lower levels of plasma viremia and higher CD4+ T cell counts than men in the absence of 
antiretroviral therapy (ART)[5]. While viral loads in acute infection display sex-
dependent variability, progression to AIDS between men and women occurs at similar 
rates [5]. While a variety of geographic and socioeconomic issues are critically important 
factors affecting sex-dependent differences, especially in sub-Saharan Africa where rates 
of new HIV-1 infections are highest, little is known about the contribution of human 
biology to sex disparities [6]. 
 A precedent for sex-dependent differences in myeloid cells was established with 
the discovery of sex bias in plasmacytoid dendritic cell (pDC)-mediated responses to 
HIV-1. Female-derived pDCs exhibit more robust interferon (IFN) responses to infection 
in a TLR7-dependent manner [7]. Exposure to several estrogen steroid hormones in vitro 
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results in induction of IFN- and interleukin (IL)-driven antiviral responses [8-10]. IFNs 
themselves have been shown to be important players in sites of transmission such as the 
female reproductive tract, indicating differential expression of interferon-stimulated 
genes (ISGs) may play an important role in sex differences in viral and bacterial 
infections [11, 12]. Though these studies provide novel insights into sex-dependent 
differences in virus transmission, the cellular and molecular mechanisms underlying 
these differences remain unknown. 
 In the present study, we sought to elucidate whether intrinsic differences in 
macrophage and CD4+ T cell susceptibility to HIV-1 exist between males and females in 
vitro. We report that female-derived macrophages potently resist infection with HIV-1, 
and that their capacity for HIV-1 restriction relative to males is independent of virus and 
is effected prior to integration. We show that SAMHD1, a well-known anti-HIV-1 
restriction factor expressed in immune cells, exhibits sex-dependent regulation in 
macrophages but not in CD4+ T cells and largely explains the infectivity differences. 
Thus, the ability of SAMHD1 to restrict viral infection is influenced by sex, and may 
inform future studies aimed at understanding the molecular basis for sex differences in 
HIV-1 pathogenesis.  
 
Results 
Sex influences macrophage infection with HIV-1 
 To investigate the role of sex in HIV-1 infection, healthy donors were recruited in 
male/female pairs. Monocyte-derived macrophages (MDM) were infected with two 
replication-competent virus clones, HIV-1-NL-4-3-BaL-IRES-HSA and HIV-1-NL-4-3-
  
17 
AD8, both R5-tropic viruses (Figure S2.1). HIV-1-NL-4-3-BaL-IRES-HSA expresses 
CD24, also known as heat stable antigen (HSA), and infection is analyzed by the 
expression of HSA the surface of infected cells[13]. HIV-1-NL-4-3-AD8 infection is 
analyzed by staining for HIV-1 p24. Macrophages were detached and analyzed via flow 
cytometry. Infection levels are expressed as % infected macrophages as determined 
percentage of HSA+ cells (HIV-1-NL-4-3-BaL-IRES-HSA) or p24+ cells (HIV-1-NL-4-
3-AD8). We observed a wide range of donor susceptibility to infection (HIV-1-NL-4-3-
BaL-IRES-HSA: 1.42-27.90% (males), 0.28-5.62% (females); HIV-1-NL-4-3-AD8: 
1.42-12.57% (males), 0.30-4.38% (females)) (Figure 2.1). If infections in male-derived 
macrophages in each donor pair were normalized to 100%, infections of female 
macrophages reached infection levels, on average, of 25% (HIV-1-NL-4-3-BaL-IRES-
HSA) and 37% (HIV-1-NL-4-3-AD8) (Figure 2.1). 
 
Sex-dependent differences in HIV-1 infection occur early, are  
independent of virus entry, and represent a preintegration 
block in female-derived MDM 
 To determine whether the observed sex-dependent difference in infectivity 
required multiple rounds of replication, MDM were generated from six healthy donors 
and infected with HIV-1-NL-4-3-AD8. Infection was tracked over a 14-day time course 
and analyzed at 2, 6, 10, and 14 days postinfection. Significant sex-dependent differences 
in infectivity were observed 2 days postinfection, and differences were compounded at 
the later time points (Figure 2.2). These results suggest sex-dependent differences are due 
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to an intrinsic difference in susceptibility that renders female-derived macrophages less 
permissive to initial infection independent of replication [14].  
 We next sought to ascertain whether the route of virus entry can explain the 
observed sex-dependent differences in HIV-1 infectivity. To this end, we generated 
replication-defective HIV-1 viruses pseudotyped with vesticular stomatitis virus 
glycoprotein (HIV-−Env-GFP/VSVG). HIV-−Env-GFP/VSVG contains a 
frameshift mutation in the envelope glycoprotein gene and is capable of only a single 
round of infection. Importantly, VSVG utilizes the low-density lipoprotein receptor, 
which shunts viruses towards an endocytic pathway that is independent of gp160-
receptor/co-receptor interactions [15]. Infection of paired male and female healthy donor 
MDM revealed differences in infectivity that mirrored those observed during infection 
with viruses encoding a natural HIV-1 envelope glycoprotein (Figure 2.2). Setting 
infection of male macrophages in each donor pair to 100%, females exhibited, on 
average, infection levels that reached 39% of those observed in paired male counterparts 
(Figure 2.2). Analysis of the HIV-1 receptor/co-receptors CD4 and CCR5 by flow 
cytometry revealed no differences in cell surface expression, consistent with the notion 
that the relative intrinsic susceptibility of male MDM to infection occurs at a receptor-
independent, postentry step (Figure S2.2).  
We next examined total genomic DNA of HIV-−Env-GFP/VSVG-infected 
MDM to quantify integration events in an effort to identify where in the HIV-1 life cycle 
sex differences in susceptibility to infection occur. Infection in six donor MDM was 
analyzed by flow cytometry for GFP expression, and on average, 10.6% of male MDM 
were infected compared to 2.5% of female-derived MDM. Gag-PCR revealed significant 
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differences between male- and female-derived macrophages, supporting a model wherein 
female-derived macrophages restrict HIV-1 with greater potency at a preintegration step 
(Figure 2.3). 
 
Memory CD4+ T cells do not display sex-dependent differences in infectivity 
 To determine whether observed differences in infectivity were unique to MDM or 
were also displayed by T-cells from the same donors, CD4+ T cells and MDM were 
isolated from paired male and female donors cells and were infected ex vivo via 
spinoculation with HIV-1-NL-4-3-BaL-IRES-HSA, the same viral clone utilized in 
previous experiments involving MDM infections. Unlike MDM, memory CD4+ T cells 
failed to exhibit significant sex differences in initial infectivity regardless of MOI, and 
analysis of infection at the 96-hour time point failed to reveal differences in replication 
between males and females (Figure 2.3). Similar to our experiments in MDM, we 
observed no differences in the expression of either CD4 or CCR5 (Figure 2.3). These 
experiments support a myeloid cell type-specific, sex-dependent difference in infectivity 
with HIV-1.  
 
Sex-dependent differences in MDM infectivity are SAMHD1-dependent  
SAMHD1 has been shown to potently restrict HIV-1 at a preintegration step 
through inhibition of reverse transcription [16-18]. SAMHD1 is a deoxynucleoside 
triphosphate (dNTP) triphosphohydrolase, and its activity as an HIV-1 restriction factor is 
inhibited by threonine-592 phosphorylation by destabilizing the tetramer required for its 
catalytic activity [19-21]. To examine the potential role of SAMHD1 in regulating sex-
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related differences, MDM were generated from six donors were lysed on day 7. Whole 
cell lysates were analyzed by Western Blot for levels of total SAMHD1, SAMHD1-
pT592, and -Actin. Total levels of SAMHD1 did not differ between male- and female-
derived MDM. However levels of the active enzyme, as measured by phospho-T592, 
were present at a significantly higher degree in female-derived MDM (Figure 2.4, two 
representative donor pairs shown). This represented, on average, a 2-fold increase in 
relative levels of pSAMHD1 in male- versus female-derived MDM (Figure 2.4).  
 
Sex-dependent differences are overcome through bypass of  
SAMHD1-mediated restriction 
 In view of the above results, we hypothesized that enhanced activity of SAMHD1 
was responsible for the relative restriction observed in female-derived macrophages. 
Thus we predicted that addition of an excess of exogenous deoxynucleosides (dN) would 
ablate the sex-dependent differences. dN ‘flooding’ has been shown to overcome the 
SAMHD1-mediated restriction and render macrophages generally more permissive to 
infection [16]. As shown in our previous report, dN flooding relieved baseline restriction 
and extinguished sex-based differences in infectivity, enhancing female-derived MDM 
(Donor A026) infectivity from 0.8% (no dN) to 12.8% (10mM dN) and male-derived 
MDM (Donor A006) infectivity from 2.9% (no dN) to 11.6% (10mM dN) [22]. 
 To confirm that SAMHD1 is responsible for the differences observed, we utilized 
the HIV-2 accessory protein Vpx. Vpx targets SAMHD1 for ubiquitination, leading to 
proteasome-directed proteolysis in the setting of HIV-2 infection [16-18, 23, 24]. Though 
HIV-1 does not encode Vpx, and therefore does not induce SAMHD1 degradation on its 
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own, it can be complemented with Vpx through virus-like particle (VLP)-mediated 
delivery to enhance HIV-1 infection of myeloid cells [18, 25]. In agreement with our 
experiment utilizing excess dNs to overcome the SAMHD1-mediated restriction, pre-
treatment of cells with Vpx(+)VLPs completely reversed the restrictive capacity of MDM 
(Figure 2.5, two representative donors shown). Importantly, Vpx(+)VLPs effectively 
eliminated differences in infectivity between three male- and three female-derived MDM 
(Figure 2.5). These experiments confirm that SAMHD1 is the key antiviral restriction 
factor responsible for sex-dependent differences in MDM infectivity with HIV-1.  
 
Materials and methods 
Generation of monocyte-derived macrophages and isolation  
of memory CD4+ T cells 
Peripheral blood mononuclear cells (PBMCs) were isolated from healthy-donor 
whole blood via Lymphoprep density gradient centrifugation (StemCell Technologies) 
immediately following phlebotomy. Positive selection of CD14+ monocytes was carried 
out using magnetic bead-based isolation (Miltenyi Biotec). CD14+ monocytes were 
resuspended in serum-free RPMI 1640 (Invitrogen) supplemented with 100U/mL 
Penicillin, 100ug/mL Streptomycin, 2mM L-Glutamine (Gibco), seeded at a density of 
1.0x10^6 cells/well (12-well plates, Corning) or 5.0x10^5 cells/well (24-well plates, 
Corning), and incubated for 2 hours at 37 degrees C and 5% CO2 to allow optimal 
adherence. Serum-free media was aspirated and replaced with macrophage growth media, 
consisting of RPMI 1640 supplemented with 100U/mL Penicillin, 100ug/mL 
Streptomycin, 2mM L-Glutamine (Gibco), and 12% Pooled Human Serum (Innovative 
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Research). CD14+ monocytes were cultured for 7 days in macrophage growth media 
prior to downstream analysis. Untouched memory CD4+ T cells were isolated via 
negative isolation from the remaining fraction following CD14+ monocyte isolation 
(Miltenyi Biotec). Memory CD4+ T cells were cultured for 2-5 days in macrophage 
growth media prior to infection. Infection was carried out via spinoculation at 2900rpm 
for 2 hours at 37 degrees C.  
 
Viruses and virus clones 
Replication-defective (HIV-−Env-GFP) and replication-competent (HIV-1-
BaL-IRES-HSA and HIV-1-NL4-3-AD8) were used in this study. Replication-
incompetent HIV-−Env-GFP clones contain a frameshift mutation in Env, express 
either GFP or mCherry in place of Nef, and were pseudotyped with Vesticular Stomatitis 
Virus Glycoprotein (VSVG). The replication-competent, R5 clone HIV-1-NL4-3-BaL-
IRES-HSA was a kind gift of Michel J. Tremblay (Universite Laval, Quebec City, 
Quebec), and expresses a surface-bound CD24 (HSA) from an IRES. The replication-
competent, R5 clone HIV-1-NL4-3-AD8 is a derivative of pNL4-3 (Eric O. Freed, NIH 
AIDS Reagent Program).  
 
Virus generation and infection of MDM 
Viruses were generated via calcium phosphate-mediated transfection of 
HEK293T cell with either HIV-−Env-GFP, HIV-1-NL4-3-BaL-IRES-HSA, or HIV-1-
NL4-3-AD8 clones. Supernatants were collected 36 hours following transfection and 
cryopreserved in -80 degrees C until use. Primary MDM were infected in static culture 
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for 12 hours following 7-day spontaneous differentiation by diluting 250ng of virus as 
determined by p24-ELISA in 500uL RPMI 1640. Following infection, viral supernatant 
was removed, MDM were washed twice with serum-free RPMI 1640, and media was 
replaced with macrophage growth media.  
 
Flow cytometric analysis 
Macrophages were detached from tissue culture plates via incubation with 
Accutase Cell Dissociation Reagent for 2 hours at 37 degrees C. Cells were washed and 
stained with eFluor450 Viability Dye (eBioscience). To phenotype cells, cells were 
stained with the following monoclonal antibodies: Fluorescein isothiocyanate-conjugated 
(FITC)-anti-CD14, allophycocyanin-conjugated (APC)-anti-CD16, APC-anti-CD71, and 
phycoerythrin-conjugated (PE)-anti-CD86 followed by flow cytometric analysis in a 
LSRFORTESSA X-20 (BD Bioscience). To assess viral gene expression, HIV-−Env-
GFP/VSVG-infected cells were analyzed for GFP reporter gene expression. Cells 
infected with HIV-1-BaL-IRES-HSA were stained for surface expression of CD24 with 
APC-anti-CD24 (eBioscience). Cells infected with HIV-1-NL4-3-AD8 were 
permeabilized and fixed with Cytofix/Cytoperm (BD Biosciences) for 30 minutes at 4 
degrees C, then washed with Perm/Wash Buffer (BD Biosciences) and stained with a 
1:40 dilution of anti-p24 antibody (Beckman Coulter).  
 
Discussion 
 While CD4+ T cells constitute the major target of HIV-1 and contribute to viral 
latency and persistence in vivo, mounting evidence supports an important role for 
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myeloid lineage cells in acute and chronic infection [26-31]. Specifically, macrophages 
are present in a variety of tissues, and are enriched in mucosal sites of HIV-1 
transmission [32, 33]. Additionally, macrophages and other myeloid lineage cells are 
thought to play a crucial role during chronic infection and contribute to pathogenesis in 
various anatomical sites, including the brain [34]. Persistent inflammation resulting from 
virus replication gives rise to HAND, resulting in lasting impairments that linger despite 
long-term ART [35, 36]. Recently, HIV infection in macrophages and microglia has 
shown to directly contribute to overproduction of neurodegenerative beta-amyloid 
protein, providing clues into the molecular mechanisms that contribute to HAND [37]. 
Despite the depth of knowledge regarding HIV-1 pathogenesis in CD4+ T cells, little is 
known about the role of macrophages in acute and chronic infection, and even less 
regarding their contribution to sex-based differences.  
 SAMHD1 is among the most important restriction factors determining the low 
permissivity to infection of nondividing cells such as macrophages, dendritic cells, and 
memory CD4+ T cells [16-18, 38, 39]. The expression of SAMHD1 is an important facet 
in determining the cellular susceptibility to HIV-1. Activated, cycling CD4+ T cells that 
express low levels of SAMHD1 are exquisitely sensitive to infection with HIV-1, 
whereas cells that express high levels of SAMHD1 such as macrophages resist infection 
[16-18, 40]. An important mechanism of SAMHD1 regulation in cells enriched for 
SAMHD1 expression is threonine-592 phosphorylation [19-21]. T592 phosphorylation 
leads to destabilization of the SAMHD1 tetramer which is required for its anti-HIV-1 
activity [20, 21]. In activated CD4+ T cells, SAMHD1 phosphorylation is robustly 
enhanced in order to satisfy the cell’s requirement for dNTPs in DNA synthesis [19]. 
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SAMHD1 phosphorylation in macrophages and other noncycling cells is similarly under 
dynamic control and is dependent on cues that range from growth factor signaling to 
pathogen recognition [19, 22, 41].While it has been shown that TLR7-dependent sex 
differences exist in dendritic cell susceptibility and response to HIV-1, a function for 
differential regulation of SAMHD1 between males and females has not, to our 
knowledge, been previously reported. In this report, we identify SAMHD1 regulation as a 
novel molecular mechanism underlying sex differences in infectivity of human 
macrophages.  
 The contribution of IFNs to HIV-1 restriction is well established, and multiple 
downstream mechanisms that block infection from entry to release have been studied and 
reviewed at length [42]. An important consequence of IFN signaling is the de-
phosphorylation and activation of SAMHD1, which presents a potent barrier to infection 
that can be overcome by SAMHD1 proteolysis or siRNA-mediated silencing [22]. Given 
that a sex-dependent difference has been observed in IFN production in pDCs in response 
to TLR signaling, it is formally possible that baseline differences in IFN production 
contribute to differences in MDM infection with HIV-1 [7]. A type I IFN, IFN epsilon, is 
constitutively expressed in cells of the female reproductive tract, and its expression is 
highly induced upon steroid hormone treatment [12]. This finding provides an intriguing 
avenue for future research into sex-dependent differences in HIV-1 infection, and may 
potentially play a role in the steady-state protection and SAMHD1 activity female 
macrophages exhibit ex vivo. The fact that women are disproportionately affected by 
autoimmune disorders, particularly interferonopathies such as systemic lupus 
erythematosus, warrants further investigation into differences in immunologic pathways 
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that govern both susceptibility to viral infections on one hand and chronic inflammatory 
diseases on the other. The results of the current study demonstrate the importance of 
understanding sex as a biological variable in HIV-1 infection, and the importance of 
including research participants of both sexes in clinical and basic research efforts. 
Furthermore, we establish for the first time SAMHD1 and its regulation as a critical 
component of sex differences in the control of HIV-1 infection, which may inform future 
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Figure 2.1. HIV-1 inefficiently infects female-derived macrophages. (A) Male- (blue) 
and female-derived (red) MDM infected in pairs with HIV-1-NL-4-3-BaL-IRES-HSA. 
Macrophages were stained for cell surface CD24 (HSA). Percentage infected 
macrophages represented as percentage of CD24+ cells. (B) Male- and female-derived 
MDM infected in pairs with HIV-1-NL-4-3-AD8. Macrophages were permeabilized and 
stained for intracellular p24. Percentage infected macrophages represented as percentage 
of p24+ cells. (C) Comparison of female- versus male-derived MDM infected with HIV-
1-NL-4-3-BaL-IRES-HSA. Infection of male-derived MDM in each donor pair was set 
independently to 100% and the percentage of infection in female-derived MDM 
expressed as a percentage of that observed in the male-derived MDM counterpart. (D) 
Comparison of female- versus male-derived MDM infected with HIV-1-NL-4-3-AD8. 

















Figure 2.2. Sex differences in HIV-1 infection occur early and independent of virus 
entry. (A) Monocytes from six healthy donors (three male and three female) were 
isolated on a single draw date and differentiated simultaneously. Day 7 macrophages 
were infected with HIV-1-NL-4-3-AD8 and analyzed for intracellular p24 staining on 
days 2, 6, 10, and 14. Three male donors and three female donors were averaged to 
produce a single infection curve. (B) MDM were infected on day 7 with HIV-−Env-
GFP/VSVG and analyzed 48 hours later for GFP expression. Values represented as 
percentage of GFP+ cells as analyzed by flow cytometry. (C) Infections were analyzed 
pairwise and unpaired. Infection in male-derived MDM was set to 100% and percentage 
of infection in female-derived MDM was analyzed for each pair. (D) MDM from six 
healthy donors (three males and three females) were infected with HIV-−Env-
GFP/VSVG and analyzed 48 hours postinfection for GFP expression. Genomic DNA was 


























Figure 2.3. Memory CD4+ T cells do not exhibit sex-dependent differences in 
infectivity. (A) Memory CD4+ T cells were isolated from healthy donors and infected at 
an MOI=1 with HIV-1-NL-4-3-BaL-IRES-HSA and analyzed at 48 and 96 hours post-
infection. (B) Memory CD4+ T cells isolated from healthy donors, infected at MOI=3, 
and analyzed at 48 and 96 hours postinfection. (C) Memory CD4+ cells were stained for 







Figure 2.4. Sex differences in MDM infectivity occur prior to integration and 
correlate with differences in SAMHD1 activity. (A) Representative Western Blot 
images of two representative male/female-derived MDM pairs mock infected or infected 
with HIV-−Env-GFP/VSVG probed for pSAMHD1-T592, Total SAMHD1, and -
Actin. (B) Western Blot quantification of six separate MDM (three males and three 
females) isolated and differentiated simultaneously analyzed for total SAMHD1. (C) 

















Figure 2.5. Sex differences in MDM infectivity are overcome via SAMHD1 bypass 
or Vpx-mediated SAMHD1 degradation. (A) Representative flow plots of MDM 
infected with HIV-−Env-GFP/VSVG following pretreatment with Vpx(+)VLPs. (C) 
Quantification of six donors (three males and three females) infected with HIV-−Env-




Figure S2.1. HIV-1 constructs. (A) HIV-−Env-GFP/VSVG (B) HIV-1-NL-4-3-BAL-








Figure S2.2. Entry does not play a role in sex-dependent differences in MDM 
infectivity or CD4+ T cell phosphorylation. (A) MDM in six healthy donor-derived 
macrophages from were analyzed for CD4 and CCR5 expression via flow cytometry. (B) 
Analysis of pSAMHD1 levels by Western Blot in six memory CD4+ T cells isolated 
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Macrophages are susceptible to HIV-1 infection despite abundant expression of a 
variety of antiviral proteins, perhaps most importantly the restriction factor sterile alpha 
motif domain and histidine/aspartic-acid domain-containing protein 1 (SAMHD1). We 
investigated the role of SAMHD1 and its phosphodependent regulation in the context of 
HIV-1 infection in primary human monocyte-derived macrophages and the ability of 
various interferons and pharmacologic agents to modulate SAMHD1. Here we show that 
stimulation by type I, type II, and type III interferons converges upon activation of 
SAMHD1 via dephosphorylation at Threonine-592. CDK1, a known effector kinase for 
SAMHD1, was transcriptionally downregulated by all IFN types tested. Pharmacologic 
inhibition or siRNA-mediated knockdown of CDK1 phenocopied the effects of IFN on 
SAMHD1. A panel of FDA-approved tyrosine kinase inhibitors potently induced 
activation of SAMHD1 and subsequent HIV-1 inhibition. The viral restriction enforced 
via IFNs or Dasatinib could be overcome through bypass of SAMHD1, proving that their 
effects are exerted primarily through this pathway. Our results demonstrate that 
SAMHD1 activation, but not and increases in mRNA or protein induction, is the 
predominant mechanism of HIV-1 restriction induced by type I, type II and type III IFN 
signaling in macrophages, and presents a pharmacologically actionable target through 
which HIV-1 infection can be subverted. 
 
Introduction 
Macrophages are major targets of HIV-1 and their importance in infection 
establishment, progression, and persistence has been studied at length [1, 2]. They are 
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important contributors to virus amplification and dissemination during primary infection, 
and in the central nervous system (CNS), HIV-1-infected macrophages and microglia 
precipitate a spectrum of neurological impairments that persist in the setting of 
antiretroviral therapy[3-5]. It is known that macrophages exhibit low permissiveness to 
infection, in part due to the constitutive expression of the antiviral restriction factor SAM 
domain- and HD domain-containing protein 1 (SAMHD1), a deoxynucleoside 
triphosphate (dNTP) triphosphohydrolase which restricts HIV-1 by maintaining dNTP 
concentrations below the threshold required for efficient reverse transcription (RT)[6-8]. 
SAMHD1 is regulated at the level of phosphorylation by type I interferon (IFN), but to 
what extent type II and III IFNs affect SAMHD1 phosphorylation, and whether 
SAMHD1 is required for their activity, remains unknown [9].  
IFNs play an important role in preventing viral infection through multiple effector 
mechanisms. Numerous studies have pointed to enhanced expression of various 
restriction factors that act at multiple stages of HIV-1 infection, including APOBEC-
family proteins, MX2, GBP5, and others, to explain the potent antiviral effects of IFNs 
[10-13]. In this context, activation of interferon regulatory factor (IRF) family of 
transcription factors, nuclear translocation, and recognition of a conserved DNA 
sequence known as an IFN-stimulated response element (ISRE) present in the promoter-
enhancer region of a number of genes direct a number of antiviral programs [14, 15]. 
Though IFN and IFN are perhaps the most well-studied type I IFNs, numerous others 
exist in humans including IFN, whose relevance in HIV-1 restriction has been 
demonstrated recently in macrophages [16]. The sole member of the type II IFN family, 
IFN, is widely recognized for its role in macrophage activation, and was recently shown 
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to induce a potent, Env-dependent block to HIV-1 infection in CD4+ T cells that was 
distinct from that induced by type I IFN [17]. The Type III IFNs, which include IFN1, 
2, and 3, have been shown to exhibit anti-HIV-1 activity, and may be relevant in 
specific tissue sites such as the vaginal mucosa [18]. Macrophages are highly responsive 
to the modulating effects of many diverse interferons and interferon-like molecules. 
However, the mechanisms underlying the potent anti-HIV-1 capacities of diverse IFNs 
remain incompletely defined [19]. 
In this study, we examined the abilities of divergent IFN families to inhibit HIV-1 
infection in primary human MDM, and provide mechanistic insight into the major 
effector function of type I, type II, and type III IFNs. We extended the study to explore 
the HIV-1 restriction potential of a panel of FDA-approved tyrosine kinase inhibitors 
(TKI), in an effort to define SAMHD1 as a potential pharmacologic target for anti-HIV-1 
efforts. These studies show that SAMHD1 serves as the key regulator of HIV-1 




Type I, type II, and type III IFNs induce SAMHD1-T592 dephosphorylation,  
resulting in enhanced restriction of HIV-1 infection in MDM 
We sought to determine whether IFNs from various families could differentially 
modulate SAMHD1 protein levels or activity and whether these changes would in turn 
affect HIV-1 infection in macrophages. CD14+ monocytes were isolated from peripheral 
blood mononuclear cells (PBMC) from healthy donors and generated MDM following 7-
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day differentiation. MDM were exposed for 24 hours to 50ng/mL concentrations of 
IFN, IFN, IFN, or IFN. Macrophages were infected with a replication-competent 
R5-tropic recombinant virus (HIV-1-BAL-HSA; Figure S2.1) [20] and analyzed for 
CD24 (HSA, mouse heat stable antigen) expression by flow cytometry 48 hours later 
(Figure 3.1). Without IFN treatment, infection levels ranged between 1 and 16% among 
donors. Because of the high degree of variability in infectivity among donors, we set 
infection levels in the absence of IFN to 100% for each individual donor, then normalized 
infection in the presence of IFN to that value (Figure 3.1). In each case, IFN treatment 
restricted infection, albeit to varying degrees: IFN, IFN, and IFN potently suppressed 
infectivity. In contrast, IFN reduced infectivity modestly and in a highly variable 
manner, a degree of protection that could not be enhanced by increasing concentrations of 
IFN (Supplemental Figure 3.2).  
To determine whether the effects of IFN are dependent on viral entry, we utilized 
a replication defective virus pseudotyped with vesicular stomatitis virus glycoprotein 
(HIV-1Env-GFP/VSVG; Figure S2.1). VSVG binds to the low-density lipoprotein 
receptor for entry and shunts the virus towards the endocytic pathway, bypassing 
membrane fusion resulting from gp120 interaction with CCR5 [21]. HIV-1Env-
GFP/VSVG was sensitive to each IFN tested, with IFN exhibiting the least potency and 
highest variability donor-to-donor, suggesting that the antiviral effector mechanisms 
induced by various IFNs are independent of both the route of viral entry and virus 
production (Figure 3.1).  
To examine the role of SAMHD1 in restriction by the various IFN types, we 
generated cell lysates from MDM treated with IFN for 24 hours and probed for total 
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SAMHD1 and pSAMHD1-T592 (Figure 3.1; two representative donors shown). Addition 
of recombinant IFN, IFN, or IFN led to a reduction in SAMHD1 phosphorylation that 
correlated directly with reduced infectivity by HIV-1Env-GFP/VSVG (p<0.0001, 
R2=0.9783; Figure 3.1). The levels of total SAMHD1 protein were not affected by any of 
the IFNs tested, and there was no correlation between total SAMHD1 protein and 
infectivity following IFN stimulation (Figure 3.1). SAMHD1 activation through T592 
dephosphorylation is thus a conserved effector mechanism resulting from stimulation of 
MDM by different IFN types. 
 
SAMHD1 is active at baseline and controls MDM resistance to HIV-1 
 We hypothesized that highly permissive MDM would exhibit a higher degree of 
phosphorylation in SAMHD1, relative to the levels of total SAMHD1 protein. We 
derived MDM from six healthy donors and exposed them to HIV-1Env-GFP/VSVG. In 
the absence of stimulation, MDM from these donors exhibited vastly different levels of 
SAMHD1 phosphorylation (Figure 3.2) at baseline which correlated directly with the 
levels of infectivity (p=0.045, R2=0.6748; Figure 3.2). Infectivity did not correlate with 
levels of total SAMHD1 protein (Figure 3.2). Although a modest correlation between 
CCR5 cell surface expression and infectivity was observed, differences in infectivity at 
baseline cannot be attributed to potential fluctuations in CD4 or CCR5 because the virus 
used in these experiments was pseudotyped with VSVG (Data Not Shown). The finding 
that MDM from healthy donors exhibit diverse signatures of SAMHD1 activity that 
correlate directly with infectivity supports our model in which infectivity in MDM 
depends on SAMHD1 activity and not expression.  
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SAMHD1 phosphorylation status is sufficient to explain IFN-induced  
HIV-1 restriction in primary MDM 
To evaluate whether SAMHD1 is the relevant antiviral effector responsible for 
the HIV-1 restriction induced by IFNs, we delivered the SIVmac accessory protein Vpx 
to ectopically induce SAMHD1 degradation [6-8, 22-24]. We generated VSVG-
pseudotyped virus-like particles (VLP) containing the SIVmac accessory protein Vpx 
(Vpx(+)VLP) and, as a control, VLPs lacking Vpx (Vpx(-)VLP) [8, 22]. 
Cells were exposed to Vpx(+)VLPs or Vpx(-)VLPs for 6 hours then treated for 18 
hours with IFN. After VLP addition, cells were infected with HIV-1Env-GFP/VSVG. 
SAMHD1 degradation by Vpx(+)VLP and Vpx(-)VLP was evaluated by Western Blot at 
24 hours post-VLP addition and infection levels were evaluated by flow cytometry 48 
hours postinfection. Vpx(+)VLPs led to efficient SAMHD1 degradation, and addition of 
Vpx(+)VLPs effectively reversed the block to infection with HIV-1Env-GFP/VSVG 
while Vpx(-)VLPs failed to promote infection (Figure 3.3, one representative donor; 
additional donors shown in Figure 3.3). Vpx(+)VLP-mediated reversal of the IFN-
induced antiviral state occurred in the context of SAMHD1-T592 dephosphorylation and 
without overt changes in SAMHD1 total protein levels (Figure 3.3). Cells not treated 
with IFN also demonstrated increased infectivity when treated with Vpx(+)VLP, 
consistent with previous reports showing that Vpx can overcome the restriction imposed 
by SAMHD1 at baseline, in the absence of exogenous IFN stimulation, proving that 
SAMHD1 is at least partially active under unstimulated conditions (Figure 3.3) [22]. 
SAMHD1 has two reported antiviral activities: it has been proposed to act both as 
a nucleotide triphosphohydrolase and as a ribonuclease [25-27]. To determine whether 
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SAMHD1 activation results in a state of HIV-1 restriction that relies on limiting dNTP, 
we exposed cells to high concentrations of deoxynucleosides (dNs) in the culture medium 
prior to infection. We predicted that exogenous dN administration would phenocopy the 
effect of Vpx(+)VLPs and reverse the IFN-induced antiviral activity. 
Deoxyribonucleosides (dNs) are cell-membrane permeable and are converted to dNTPs 
once inside the cell (Lahouassa, 2012, 22327569). Addition of dNs to the medium 
enhanced infection in the absence of IFN and completely relieved the IFN-induced 
restriction in IFN-treated cells (Figure 3.3; two representative donors shown). These 
results, together with those in Figures 3.3, establish SAMHD1 dephosphorylation as the 
principal effector mechanism against HIV-1 in the response of MDM to types I, II, and 
III IFN, which results in dNTP depletion and impaired HIV-1 RT.  
 
Canonical HIV-1 restriction factors, but not SAMHD1, are transcriptionally  
induced by type I, type II, and type III IFN stimulation 
 We next sought to ascertain whether SAMHD1 was a bona fide type I, type II, or 
type III ISG in MDM, or whether SAMHD1-dependent, IFN-induced HIV-1 restriction 
could be attributed to post-translational protein modifications only. MDM were left 
untreated or stimulated with IFN, IFN, and IFN, or IFN. mRNA was isolated 18 
hours following stimulation and subject to RNA-sequencing. Figure 3.4 shows the Log2 
fold-change (sequence reads in IFN treatment over those without IFN) in mRNA for 
SAMHD1 along with a small subset of known ISGs (ISG15, ABOBEC3A, SIGLEC-1, 
and MX1, MX2, OAS1), cell cycle regulators known to act on SAMHD1 (CDK1, 2, 4 
and 6) and immune-related genes (CD4, CCR5, CXCR1, CD180). SAMHD1 mRNA 
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levels were not dramatically affected by any of the IFN treatments (1.08-fold (IFN), -
1.24-fold (IFN), 1.27-fold (IFN), and 1.21-fold (IFN)). In contrast, all tested ISGs 
were strongly induced by each of the IFNs tested, exhibiting expression levels that ranged 
between 5-fold (ISG15 by IFN) and 750-fold (APOBEC3A by IFN) over the no-IFN 
condition (Figure 3.4).  
Among the cyclin-dependent kinases examined in our RNAseq experiment, 
CDK1 mRNA was decreased 5.7-fold, 3.9-fold, and 20.8-fold after IFN, IFN, and 
IFN, respectively (Figure 3.4). CDK1 transcripts were modestly upregulated by IFN 
(1.4-fold), the only IFN with modest to undetectable HIV-1 restriction in our studies. 
Therefore, we speculated that downregulation of CDK1 by IFN, IFN, and IFN is part 
of the mechanism by which these IFNs induce dephosphorylation of SAMHD1. To verify 
this prediction, we tested the CDK1/CDK2 BMS-265246 inhibitor for its ability to 
restrict HIV-1Env-GFP/VSVG infection. BMS-265246 restricted HIV-1 infection in 
MDM, whereas GW2580, a TKI that targets CSF-1R among other RTKs, had no effect 
(Figure 3.5) [28]. 
 We next performed siRNA to CDK1 to verify its role in SAMHD1 
phosphorylation and HIV-1 restriction. Knockdown of CDK1 resulted in a significant 
reduction in SAMHD1 phosphorylation, concomitant with a reduction in MDM 
susceptibility to HIV-1, while siRNA targeting SAMHD1 led to an enhanced 
susceptibility of MDM to HIV-1 (Figures 3.5). In agreement with our findings with 
Vpx(+)VLPs, knockdown of SAMHD1 similarly reversed the IFN-induced restriction to 
HIV-1, suggesting the majority of the antiviral effect is exerted through SAMHD1 
activation (Figure 3.5).  
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SAMHD1 activity can be regulated pharmacologically 
Because activation of SAMHD1 imposes a potent blockade against HIV-1, it 
would be ideal if the activity of SAMHD1 could be controlled pharmacologically. 
Recently, it was shown that this can be accomplished in CD4+ T cells with the use of 
Dasatinib, a Bcr-Abl-specific TKI FDA-approved for use in chronic myelogenous 
leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia 
(Ph+ AML) [29, 30]. We tested a panel of tyrosine kinase inhibitors to determine whether 
they possess anti-HIV-1 activity and whether that activity stems from SAMHD1 
dephosphorylation. Among the TKIs tested were Dasatinib (DAS), Bosutinib (BOS), 
Crenolanib (CRE), Palbociclib (PAL), and Ponatinib (PON). These compounds are FDA-
approved and target a variety of cellular pathways including Abl Kinase, Src-family 
kinases, type III receptor tyrosine kinases, as well as CDK4 and CDK6 [31]. Each 
inhibitor led to HIV-1 restriction, with DAS providing the most potent HIV-1 blockade 
(Figure 3.6). HIV-1Env-GFP/VSVG infectivity was inversely correlated with the 
proportion of SAMHD1 present in its activated, dephosphorylated state as manipulated 
by the TKIs (Figure 3.6). We focused on Dasatinib to test whether SAMHD1 
phosphorylation and infectivity exhibited a dose-dependent relationship, and observed 
overt changes in pSAMHD1-T592 that corresponded to increasing concentrations (Figure 
3.6). The dephosphorylation of SAMHD1 was concomitant with and inversely 
proportional to the infectivity by HIV-1Env-GFP/VSVG (Figure 3.6).  
TKIs, including DAS, target diverse cellular pathways at high nanomolar 
concentrations [32]. If SAMHD1 is indeed responsible for the effects of the TKIs tested, 
then incubation with Vpx(+)VLP following treatment should induce degradation of 
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SAMHD1 and overcome the TKI-imposed restriction. Incubation with DAS rendered 
cells highly resistant to infection (0.5%) when compared with untreated cells (6.0%), 
representing a 92% protection (Figure 3.6). Addition of Vpx(+)VLP to untreated cells 
enhanced infection 8.8-fold (6.0% to 53.0%) while addition of Vpx(+)VLP in the context 
of DAS enhanced infection 76-fold (0.5% to 38%), representing a reversal of the DAS-
induced antiviral state. Taken together, our experiments establish a causal link between 
SAMHD1 activation and protection from HIV-1 infectivity in MDM, and provide 
evidence to support a dynamic regulatory role for SAMHD1 in MDM. Furthermore, we 
demonstrate that SAMHD1 activity can be manipulated pharmacologically to render 
macrophages refractory to HIV-1 infection. 
 
Materials and methods 
Isolation of healthy donor PBMCs 
Healthy donors age 18 and older were recruited for this study under the 
University of Utah Institutional Review Board (IRB) protocol #676637. Written informed 
consent was obtained from all donors. Whole blood was obtained by peripheral 
phlebotomy and peripheral blood mononuclear cells (PBMC) were isolated using a 
Lymphoprep density gradient (Stemcell Technologies).  
 
Generation and infection of MDM 
CD14+ monocytes were isolated via positive selection with magnetic beads 
(Miltenyi Biotec). Cells were allowed to adhere in serum-free media for 2 hours, which 
was then removed and replaced with RPMI + 10% pooled human serum (Innovative 
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Research). Media was changed at day 5, and cells were cultured for a total of 7 days to 
allow differentiation to MDM prior to experimentation as previously described. MDM 
were infected with 250ng of either HIV-1-BAL-HSA or HIV-1Env-GFP/VSVG as 
determined by p24 ELISA for 6 hours. Cells were washed twice with fresh media to 
remove unbound virus. Infection was quantified via flow cytometry at 48 hours post-
infection.  
 
Generation of viruses 
Replication-defective virus (HIV-1Env-GFP/VSVG) was generated using 
calcium-phosphate-mediated transfection of HEK293T cells. Briefly, HIV-1Env-GFP 
and VSVG plasmids were co-transfected for 6 hours. Transfection media was removed 
and cells were cultured over 2 days, with virus-containing supernatants removed at 24 
and 48 hours post-transfection. These viruses contain a frameshift mutation in envelope 
and are capable of only a single-round infection when Env is provided in trans as 
previously described [33]. Replication-competent virus (HIV-1-BAL-HSA) was 
generated through a similar transfection protocol using a single plasmid (pNL-43-BAL-
IRES-HSA) courtesy of Dr. Michel Tremblay (Centre Hospitalier de l'Université Laval). 
All viruses were quantified using p24 ELISA (Zeptometrix) and stored at -80° Celsius 
until further use.  
 
RNAseq analysis for ISGs 
MDM were generated as described.  and stimulated with 25ng/mL of the 
indicated IFNs. Total RNA was isolated 18 hours following stimulation using RNeasy 
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Mini Kit (Qiagen). Intact poly(A) RNA was purified from total RNA samples (100-500 
ng) with oligo(dT) magnetic beads and stranded mRNA sequencing libraries were 
prepared as described using the Illumina TruSeq Stranded mRNA Library Preparation Kit 
(RS-122-2101, RS-122-2102). Purified libraries were qualified on an Agilent 
Technologies 2200 TapeStation using a D1000 ScreenTape assay (cat# 5067-5582 and 
5067-5583). The molarity of adapter-modified molecules was defined by quantitative 
PCR using the Kapa Biosystems Kapa Library Quant Kit (cat#KK4824). Individual 
libraries were normalized to 10 nM and equal volumes were pooled in preparation for 
Illumina sequence analysis. Sequencing libraries (25 pM) were chemically denatured and 
applied to an Illumina HiSeq v4 single read flow cell using an Illumina cBot. Hybridized 
molecules were clonally amplified and annealed to sequencing primers with reagents 
from an Illumina HiSeq SR Cluster Kit v4-cBot (GD-401-4001). Following transfer of 
the flowcell to an Illumina HiSeq 2500 instrument (HCSv2.2.38 and RTA v1.18.61), a 50 
cycle single-read sequence run was performed using HiSeq SBS Kit v4 sequencing 
reagents (FC-401-4002). 
 
Inhibitors and IFNs 
Recombinant human IFN (PBL Assay Science), IFN (EnQuire Bio), IFN 
(Peprotech), and IFN (Peprotech) were purchased from the indicated suppliers, 
resuspended at 50ng/L, and added to cell culture at the indicated concentrations. 
Inhibitors were purchased from suppliers and resuspended at a concentration of 1mM and 





Our experiments demonstrate that SAMHD1 dephosphorylation at threonine-592 
represents a central mechanism of HIV-1 restriction that is common to the three known 
families of IFNs, though with vastly different efficiencies, as evidenced by the limited 
potency of IFN. Enhanced dNTPase activity appears to be the functional outcome of 
SAMHD1 activation, supported by several lines of evidence, including complete reversal 
of the IFN-induced restriction by addition of exogenous dNs and degradation of 
SAMHD1 by the SIV protein Vpx [8, 22]. The finding that diverse IFNs are functional to 
the degree to which they modulate SAMHD1 phosphorylation and activation without 
effecting changes in total protein is an important step in understanding innate immune 
responses in macrophages. We further report a previously undescribed activity of the type 
I IFN which display antiviral activity comparable to other type I and type II IFNs, as 
well as the type III IFN, that activate SAMHD1. While the ability of IFN to induce a 
state of HIV-1 resistance in macrophages involving generation of reactive oxygen species 
has been recently reported, we identify its major effector function in SAMHD1 activation 
[16]. Finally, we show that HIV-1 inhibition by various FDA-approved TKIs is 
dependent on the activation of SAMHD1, providing important mechanistic understanding 
as to how these compounds act and can be directed towards HIV-1 cure efforts.   
Macrophages are important targets of HIV-1 infection in vivo, and their 
significance to infection establishment and viral persistence is only beginning to be 
understood. It has been speculated that macrophages can support HIV-1 infection and 
harbor virus over prolonged periods of time independent of T cells, even in the setting of 
ART, a hypothesis that has recently been strengthened by experiments conducted in 
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humanized myeloid-only mice [1, 34]. Therefore, strategies that aim to prevent virus 
spread to tissue macrophages, either independently or in the context of latency reversal 
strategies, will be important components of ongoing HIV-1 cure efforts.  
SAMHD1 was first identified as the human homolog of a previously described 
mouse IFN-inducible GTP-binding protein known as MG11[35, 36]. Recently, 
SAMHD1 has been shown to be induced by stimulation with type I and type II IFNs via 
downregulation of miR-181 and miR-30a in human monocytes [37]. A similar phenotype 
was observed in astrocytes and microglia and was also dependent on miR181a [38]. In 
hepatocytes, it has been shown that IFN can induce SAMHD1 transcription, inducing an 
antiviral state that restricts Hepatitis B Virus (HBV) infection [39]. Additionally, it has 
been shown that in mature DCs, co-culture with lymphocytes can lead to downregulation 
of SAMHD1 and enhance DC permissiveness to HIV-1 [40]. In the present study, we 
show that the type I, II, and II IFN-induced HIV-1 restriction in MDM is not derived 
from changes in SAMHD1 protein or mRNA levels, and that the antiviral state hinges 
upon changes in SAMHD1 activity as determined by T592 phosphorylation. 
It has been previously reported that IFN is a potent modulator of HIV-1 
infectivity that acts at a preintegration step [41] dependent on the ubiquitin-proteasome 
pathway [42]. These observations came prior to the discovery that SAMHD1 was the 
cellular protein counteracted by Vpx [7, 8]. It was later shown that in dendritic cells, the 
IFN-induced block to HIV-1 involved, at least in part, SAMHD1[43]. In cycling cells, 
SAMHD1 can be activated through T592 dephosphorylation in the presence of IFN [9]. 
Most recently, it has been appreciated that artificial ‘stimulation’ of MDM through the 
addition of fetal bovine serum during differentiation can push MDM toward a G1-like 
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state that renders them more permissive to HIV-1, concomitant with an increase in 
SAMHD1 T592 phosphorylation and expression of other proteins responsible for cell-
cycle regulation [44]. While the signals responsible for the G1-like state in MDM 
remained uncharacterized, it is clear that MDM respond to mitogenic stimuli despite their 
status as terminally differentiated, postmitotic cells.   
The activity of SAMHD1 in lymphocytes is regulated by cyclin/cyclin-dependent 
kinase-mediated (CDK) threonine-592 phosphorylation in a cell cycle-dependent manner 
[9]. However, SAMHD1 phosphorylation can also be regulated independent of cell 
division [44]. MDM differentiate from monocytes to assume a postmitotic state. 
Therefore, it is striking that cell-cycle regulatory elements that could be viewed as 
dispensable in these cells are not only present but maintain a critical role in regulating 
SAMHD1 phosphorylation in response to IFN stimulation and also in response to DNA 
damage [44]. The specific CDKs responsible for SAMHD1 kinase activity depend on cell 
type, with CDK1, CDK2, CDK4, and CDK6 all demonstrating a regulatory effect on 
SAMHD1 in different contexts [9, 45, 46]. Phosphorylation of residue T592 impaired 
SAMHD1 tetramerization resulting in diminished capacity for dNTP hydrolysis and 
impaired anti-HIV-1 activity [47, 48]. Our results reveal that IFN-induced activation of 
SAMHD1 is effected via downregulation of CDK1 mRNA and suggest that in the 
absence of stimulation, CDK1 maintains SAMHD1 phosphorylated and, to a large extent, 
inactive. While it is formally possible that other IFN-unresponsive cell-cycle-related 
proteins act on SAMHD1, further studies will be required to determine their specific 
contribution to SAMHD1 dynamics in macrophages [45, 46]. 
The finding that diverse IFNs converge on SAMHD1 activation reveals a 
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common denominator in IFN signaling, despite differences in expression of numerous 
other documented antiviral genes in response to IFN stimulation [10-13]. Importantly, 
our study shows that SAMHD1 activation serves as a critical function of diverse IFN 
signaling that drives their antiviral capacity. While we did not directly address the input 
of other IFN-stimulated antiviral genes, such as APOBEC-family proteins or MX2, these 
genes are not targeted by SIVmac/smm Vpx. Indeed, a recent study showed that SIV of 
red-capped mangabeys and mandrills (SIVrcm/mnd-2) enhance HIV-1 infection in 
resting CD4+ T cells in a SAMHD1- and dNTP-pool independent manner. However, 
Vpx from these strains were unable to enhance infection in macrophages and also failed 
to induce degradation or dephosphorylation of SAMHD1 [49]. Thus, the near-complete 
abrogation of IFN antiviral activity by SIVmac Vpx implicates SAMHD1 as the major 
player in the IFN-indued antiviral state.  
SAMHD1 has recently been proposed as a potential tumor suppressor, and in fact, 
many FDA-approved anticancer TKIs have potent effects on SAMHD1 activation in vitro 
and in vivo [29, 30, 46]. In cancer, SAMHD1 is thought to play a role in controlling cell 
cycle of tumor cells, where its activity as a triphosphohydrolase can restrain uncontrolled 
cellular proliferation by blunting cellular DNA synthesis [50]. Expanding our study 
beyond the natural biology of HIV-1 infection, we show that SAMHD1 activity can be 
targeted by several FDA-approved anticancer TKIs. TKIs exerted their anti-HIV-1 
activity through SAMHD1-T592 dephosphorylation, revealing two possibilities regarding 
their activity. Though not formally tested, it will be interesting to understand whether the 
anti-HIV-1 activity of TKIs results from direct inhibition of CDKs known to 
phosphorylate SAMHD1, or whether kinase cascades affected by TKIs converge on 
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CDKs to maintain steady-state levels of SAMHD1 phosphorylation and inactivity. The 
results of our inhibitor studies, using TKIs known to target receptor tyrosine kinases 
(RTK), would suggest that signaling events originating at the cell surface may be crucial 
determinants of SAMHD1 dynamics in macrophages. While the precise signals leading to 
changes in SAMHD1 activity remain unknown, future studies aimed at delineating these 
pathways will be important in understanding how SAMHD1 activity is controlled at 
steady state and can be manipulated therapeutically. Targeting the relevant pathways may 
prove useful in anti-HIV-1 efforts or in preventing end-organ damage observed in 
patients on ART, including HIV-1 associated neurologic dysfunction.  
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Figure 3.1. Diverse IFNs restrict HIV-1 in MDM and induce SAMHD1 
dephosphorylation. (A) Flow cytometric analysis of MDM infected with replication-
competent HIV-1-BAL-HSA. Numbers indicate %CD24+ cells. (B) Flow cytometric 
analysis of MDM infected with HIV-1Env-GFP/VSVG. Numbers indicate %GFP+ 
cells. (C) MDM lysates (10g) from representative donors (A031 and A049) were 
analyzed by Western Blot for pSAMHD1-T592, total SAMHD1, and -actin. (D) 
Correlation between pSAMHD1-T592 and %GFP+ or (E) total SAMHD1 and %GFP+ 














Figure 3.2. Macrophages exhibit diverse pSAMHD1-T592 signatures at baseline 
that correlate with infectivity. (A) MDM lysates from n=6 donors were analyzed by 
Western Blot in for pSAMHD1-T592, total SAMHD1, and actin. Numbers indicate the 
proportion of pSAMHD1-T592/total SAMHD1 as calculated by Western Blot 
densitometry. Lanes were cut following development of a single membrane to remove 
alternating lanes. (B) Correlation between pSAMHD1-T592 and %GFP+ macrophages as 









Figure 3.3. SAMHD1 is the major downstream effector of diverse IFN types. (A) 
Representative Western Blot analysis of No VLP-, Vpx(-)VLP-, and Vpx(+)VLP-treated 
MDM extracts probed for pSAMHD1-T592, Total SAMHD1, and -actin. (B) 
Representative flow cytometric analysis of viable MDM infected with a replication-
incompetent HIV-1Env-GFP/VSVG in the presence or absence of 50ng/mL IFN, 
IFN, IFN, or IFN, (rows) and treated with the Vpx VLP indicated (columns). 
Numbers indicate percentage of events falling within the GFP+ gate as established with 
mock infected MDM. (C) Western Blot analysis of pSAMHD1-T592, total SAMHD1, 
and actin for donor A051. (D) Bar graphs of n=3 additional, independent donors with 
each condition conducted in triplicate. (E) Data summary showing Fraction Infected with 
each IFN treatment in the absence of Vpx VLPs. (F) Data summary showing Fraction 
Infected with each IFN treatment in the presence of Vpx VLPs. (G). Donors A006 and 
A026 treated with IFN and exposed to 10mM dN then infected with HIV-1Env-
GFP/VSVG. Bars indicate the %GFP-positive cells within the viable population as 












Figure 3.4. SAMHD1 is not a canonical ISG in MDM. (A-D). Gene expression 
signatures of select genes represented as Log2 Fold Change relative to the untreated 











Figure 3.5. siRNA to CDK1 and SAMHD1 reveal central roles in IFN-induced HIV-
1 restriction. (A) Western Blot analysis of siRNA-treated MDM (densitometry bar 
graphs (B) The effect of CDK1/2 inhibition on infection with HIV-1Env-GFP/VSVG 
was determined by flow cytometry, with infection in untreated cells set to 100%. N=3 
representative donors shown. (C) Representative siRNA flow cytometry plots from two 
donors. (D) Representative flow cytometry plots from IFN-treated MDM with and 












Figure 3.6. SAMHD1 is a required for TKI-induced restriction. (A) Summary flow 
cytometric analysis of HIV-1 infection in four separate donors treated with various TKIs. 
Values indicate the %GFP-positive cells within the viable population of cells infected 
with HIV-1Env-GFP/VSVG. (B) Western Blot analysis of MDM lysates from two 
representative donors treated with the indicated concentration of Dasatinib. (C) 
Correlation between relative pSAMHD1-T592 and infectivity for six donors treated with 
0nM (gray), 50nM (light blue), and 100nM (dark blue) Dasatinib. (D) MDM treated with 
500nM Dasatinib and treated with the Vpx VLP indicated. Numbers represent the 
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 Macrophages are major targets of HIV-1 and contribute substantially to the anti-
viral response following infection. As innate immune cells, macrophages sense and 
respond to viral infection through a variety of mechanisms that often converge on the 
production and release of interferons. Interferons trigger multiple host defenses aimed at 
achieving an antiviral state, including expression of numerous interferon-stimulated 
genes that target HIV-1 at multiple stages of the virus life cycle. A major consequence of 
interferon signaling is the activation of SAMHD1. Here, we show that like type I and 
type II interferons, infection with HIV-1 elicits SAMHD1 activation and induces an anti-
viral state that protects bystander macrophages from subsequent challenge. Interestingly, 
infection with HIV-1 fails to induce significant levels of interferons at the transcriptional 
level. In this study, we aim to delineate the precise mechanisms by which HIV-1 is 
sensed in primary macrophages and the signaling pathway leading to SAMHD1 
dephosphorylation. Furthermore, we wish to establish a mechanistic basis for SAMHD1 
activation in the presence of interferons, infection with HIV-1, or tyrosine kinase 
inhibition which phenocopies these effects.  
 
Introduction 
 A major consequence of HIV-1 recognition by immune cells is the production of 
proinflammatory cytokines, which results in a state of chronic inflammation in both 
treated and untreated HIV-1 infection [1, 2]. Macrophages are equipped with numerous 
mechanisms responsible for sensing viral infection and inducing responses that prevent 
viral spread and propagation [3]. They serve as major sources of inflammatory cytokine 
  
74 
production during infection, including IL-6 and TNF-, which are important components 
of the host antiviral defense, but can be associated with increased risk to conditions such 
as neurologic, cardiovascular, liver, bone, and kidney disease [2, 4]. While the cytokines 
and cell types responsible for the double-edged sword of persistent inflammation and 
inhibition of ongoing virus replication during HIV-1 infection are well described, the 
precise signals that lead to these responses are the subject of ongoing investigation. 
Furthermore, whether HIV-1 is capable of active suppression of immune recognition and 
subsequent evasion of the antiviral response remains an open question.  
An important group of sensors involved in recognition of diverse viruses are the 
Toll-Like Receptors (TLRs). Embedded within the plasma membrane or that of 
endosomes, TLRs are members in a vast family of sensors known collectively as pattern 
recognition receptors (PRRs), due to their ability to detect common moieties present on 
the surface of infectious microbes [5, 6]. Due to their proximity to the cell surface and 
endosomal compartments, TLRs are among the first lines of defense against microbial 
infection. TLR3, TLR7, and TLR8 recognize single-stranded (ss) and double-stranded 
(ds) RNA, and are thought to contribute to HIV-1 sensing in cells of the myeloid lineage, 
specifically plasmacytoid dendritic cells (pDC) [7, 8]. TLR9 recognizes viral DNA, and 
is theoretically capable of sensing HIV-1 early during infection. However, because the 
majority of reverse transcription (RT) and generation of HIV-1 DNA occurs in the 
cytoplasm of host cells, TLR9 is unlikely to contribute meaningfully to the immune 
response to HIV-1 infection [9]. In the majority of infection settings, TLRs that sense 
foreign nucleic acids are capable of inducing IFN responses through activation of 
interferon regulatory factor (IRF)-family transcription factors [10]. Indeed, pDC-
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mediated sensing of HIV-1 via TLR7 during acute infection is thought to be a major 
driver of the IFN response observed [11]. During progressive infection, levels of 
circulating pDCs are greatly diminished, and it is thought that other cell types, such as 
macrophages, are responsible for persistent inflammation. However, failure of HIV-1 to 
induce potent proinflammatory responses in macrophages and myeloid-lineage cells 
raises key questions in the ability of HIV-1 to circumvent these defenses.  
Following entry into the host cell, viral components, otherwise referred to as 
pathogen associated molecular patterns (PAMPs), become exposed to a variety of 
sensors. Chief among these sensors in myeloid cells is cyclic GMP-AMP synthase 
(cGAS), which activates type I IFN production after binding viral DNA through synthesis 
of cGAMP and subsequent activation of stimulator of interferon genes (STING). STING 
activation triggers phosphorylation of interferon regulator factor 3 (IRF3) through 
activation of the serine/threonine kinase TANK-binding kinase 1 (TBK1). Recent studies 
have uncovered a role for cGAS-STING-mediated HIV-1 recognition in the setting of the 
HIV-2 accessory protein Vpx. Vpx targets SAMHD1 for ubiquitin-mediated degradation 
during infection with HIV-2, and is thus provided in trans during in vitro infection with 
HIV-1 to render macrophages highly susceptible to infection. However, a role for this 
signaling axis in ‘natural’ infection with HIV-1 in the absence of Vpx, and whether 
superinfection is required for sensing, remains to be determined.  
In this report, we begin to delineate the mechanisms of HIV-1 recognition in 
primary human monocyte-derived macrophages through two major approaches: phospho-
proteomic analysis of HIV-1-infected MDM and transcriptomic analysis by RNA-
sequencing (RNAseq) of HIV-1-stimulated genes. We report that infection with HIV-1 
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induces activation of SAMHD1 and elicits a state of protection from subsequent 
challenge despite the absence of a detectable IFN response. Expanding on our previous 
findings outlining a central role for SAMHD1 in regulating HIV-1 infection, we further 
sought to characterize the mechanism of SAMHD1 activation and subsequent protection 
against HIV-1 in the presence of various stimuli: HIV-1 challenge, type I, II, and III IFN 
treatments, and tyrosine kinase inhibition by Dasatinib. Here, we begin to unravel several 
pathways that provide insight into HIV-1 sensing by macrophages and the salient 
mechanisms responsible for IFN- and Dasatinib-induced MDM resistance to infection. In 




MDM infection with HIV-1 elicits SAMHD1 activation and  
protection from subsequent viral challenge 
 We first sought to determine whether infection with HIV-1 would elicit a state of 
protection from subsequent virus challenge. To this end, we generated healthy donor 
MDM and infected with either HIV-1Env-GFP/VSVG (replication-incompetent) or 
HIV-1-BaL-HSA (replication-competent). Subsequent challenge with HIV-1Env-
mCherry/VSVG 48 hours later revealed a significant protective effect, such that initial 
infection with HIV-1 exhibited inhibition of subsequent HIV-1 infection (Figure 4.1). 
Interestingly, this protection was not limited to cells that had been previously infected, as 
determined by mCherry reporter gene expression. This effect was observed whether virus 
contained native envelope or was VSVG-pseudotyped, indicating that route of entry is 
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not a major factor in determining protection from subsequent challenge (Figure 4.1). The 
protective effect did not appear to require virus replication, as cells infected with 
envelope-deleted virus were protected at least as well as cells infected with virus 
containing native envelope.  
 We generated whole cell extracts for Western Blot analysis from cells infected 
with HIV-1Env-GFP/VSVG 48 hours postinfection, the same time point at which cells 
had been infected with subsequent HIV-1Env-mCherry/VSVG. Analysis of SAMHD1 
activation revealed a marked dephosphorylation of SAMHD1 in the absence of changes 
in total SAMHD1 protein (Figure 4.1). On average, the levels of SAMHD1 
phosphorylation decreased 87% following infection (0.45 mean normalized Western Blot 
densitometry for Mock-infected cells; 0.06 mean normalized Western Blot densitometry 
for HIV-1Env-GFP/VSVG-infected cells) (Figure 4.1). Analysis of secondary infection 
over multiple donors challenged initially with HIV-1Env-GFP/VSVG- or HIV-1-BAL-
HSA showed significant restriction (21% residual infectivity, HIV-1Env-GFP/VSVG; 
17% residual infectivity, HIV-1-BAL-HSA)(Figure 4.1). These results suggest that 
macrophages sense HIV-1 infection in MDM and mount a response that leads to 
SAMHD1 activation via dephosphorylation.  
 Experiments aimed at elucidating whether SAMHD1 activation is exclusive to 
infected cells, or whether soluble signaling molecules drive bystander activation, are 
ongoing. Utilizing HIV-1-BaL-HSA, which expresses surface-bound CD24 (HSA), we 
are currently carrying out cell-sorting experiments to distinguish infected cells (CD24+) 
from bystander cells (CD24-). Preliminary experiments wherein infected-cell 
supernatants were transferred to uninfected cell cultures suggests that cell contact may be 
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a requirement for cell-to-cell communication that leads to bystander cell protection, as 
supernatants alone did not appear to induce the degree of protection observed in previous 
tests (Figure 4.2). Interestingly, it has recently been appreciated that cGAMP(2’-5’), the 
second messenger essential for cGAS-STING-mediated IFN production, is passed to 
bystander cells via gap junctions through a mechanism depedent on cell-cell contact [12]. 
Preliminary studies in our lab have confirmed the effect of cGAMP(2’-3’) on HIV-1 
inhibition in MDM, though studies are ongoing to determine whether these are the 
relevant pathways involved in MDM sensing of HIV-1 and subsequent bystander 
protection (Figure 4.3). 
 
Phospho-proteomic analysis of HIV-1-infected MDM reveals  
several key kinase pathways  
 We turned to phospho-proteomics analysis to identify signaling pathways that 
may be important for the recognition of HIV-1 and subsequent SAMHD1 activation. To 
this end, MDM were infected with HIV-1Env-GFP/VSVG. At 48 hours, infection was 
analyzed by reporter gene expression (GFP) and cells were lysed for Western Blot 
analysis. Additional cell extracts were sent for phosphoproteomic analysis utilizing the 
Kinexus Antibody Microarray KAM-900P platform. KAM-900P antibody microarray 
utilizes 613 phosphosite-specific antibodies and 265 pan-specific antibodies, allowing 
determination of changes in both total protein levels and regulatory residues that are 
manipulated by phosphorylation.  
 The results of the comparison between mock-infected and HIV-1Env-
GFP/VSVG-infected cells are summarized (Table 4.1). Interestingly, the major cyclin-
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dependent kinase (CDK) responsible for SAMHD1 phosphorylation, CDK1 was 
significantly altered [13]. CDK1 is itself subject to phospho-regulation at residues Y14 
and Y15, which are known to negatively regulate CDK1 activity[13]. Phosphorylation of 
these specific regulatory residues was enhanced 6.58-fold following infection with HIV-
1Env-GFP/VSVG, suggesting CDK1 inhibition may be a major contributor to 
SAMHD1 activation observed (Table 4.1, %CFC=558). A number of other pathways 
were indicated by the microarray, including growth factor signaling (EGFR, PDGFR). 
However inhibitor studies targeting these receptors failed to confirm a role for signaling 
in MDM (Data Not Shown). STRING protein interaction analysis revealed a central role 
for CDKs which are known to manipulate SAMHD1 activity, including CDK1, CDK2, 
and CDK4 (Figure 4.4). With these data, in concert with insights from our previous 
report, future investigations will focus on the role of CDK1 in SAMHD1 phosphorylation 
in order to better understand how a state of protection of MDM is established.    
 
Comparative analysis of IFN-, HIV-1-, and Dasatinib-stimulated genes by  
RNAseq reveals differences and similarities in the antiviral response 
 We sought to identify changes in the transcriptional landscape in an effort to 
better understand the similarities and differences between IFN-, HIV-1-, and Dasatinib-
mediated SAMHD1 activation and protection from infection with viral challenge. To this 
end, we generated MDM from the same donor used in the Kinexus Antibody Microarray 
experiment and isolated total mRNA following 24-hour treatment with the following: 
IFN, IFN, IFN, IFN, infection with HIV-1-BAL-HSA, or 500nM Dasatinib. Cell 
extracts were generated for Western Blot analysis in tandem and analyzed for SAMHD1 
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phosphorylation, which revealed activation (dephosphorylation) and protection from 
infection in accordance with previous reports (Donor A010, Figure 4.1). Analysis of 
CD24 (HSA) expression from HIV-1-BAL-HSA-infected cells revealed infection levels 
reaching 30%, which provided sufficient resolution for detection of transcriptional 
changes in a mixed population of infected (30%) and uninfected (70%) cells.   
 RNAseq revealed 83 genes found in all contrasts, and rlog differences were 
clustered (Figure 4.5). The values in the heatmap represent the amount a gene deviates in 
a specific sample from the gene’s average across all samples. Hierarchical clustering 
showed similarities between type I and type II IFNs, which differed significantly from 
Dasatinib, type III IFN, and untreated cells. Unexpectedly, HIV-1-BAL-HSA-infected 
cells did not cluster with type I and type II IFNs, strongly suggesting that HIV-1 infection 
in MDM fails to induce an interferon-stimulated gene program. Further analysis revealed 
that only one IFN, IFN, was modestly induced by HIV-1 infection (Data Not Shown). 
We selected a cutoff of Log2FC = +/-2.0 (a 4-fold induction of transcripts in either 
direction), and generated Venn Diagrams to better understand the similarities and 
differences in between HIV-1 infection and treatment with type I, II, and II IFNs. 
Strikingly, only 23 gene signatures were positively enriched in all treatments, and there 
were no shared genes exhibiting negative enrichment across all treatments (Figure 4.6). 
Pathway analysis of each treatment confirmed similarities between type I and type II 
IFNs, including positive enrichment for genes involved in interferonopathies such as 
Systemic Lupus Erythematosus and negative enrichment for genes involved in cell cycle 
control (Figure 4.6). Further analysis will be required to determine the key regulators of 
SAMHD1 control and protection afforded by initial infection with HIV-1, as well as 
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whether these regulators exhibit significant interdependency.  
 
Materials and methods 
Isolation of healthy donor PBMCs 
Healthy donors age 18 and older were recruited for this study under the 
University of Utah Institutional Review Board (IRB) protocol #676637. Written informed 
consent was obtained from all donors. Whole blood was obtained by peripheral 
phlebotomy and peripheral blood mononuclear cells (PBMC) were isolated using a 
Lymphoprep density gradient (Stemcell Technologies).  
 
Generation and infection of MDM 
CD14+ monocytes were isolated via positive selection with magnetic beads 
(Miltenyi Biotec). Cells were allowed to adhere in serum-free media for 2 hours, which 
was then removed and replaced with RPMI + 10% pooled human serum (Innovative 
Research). Media was changed at day 5, and cells were cultured for a total of 7 days to 
allow differentiation to MDM prior to experimentation as previously described. MDM 
were infected with 250ng of either HIV-1-BAL-HSA or HIV-1Env-GFP/VSVG as 
determined by p24 ELISA for 6 hours. Cells were washed twice with fresh media to 







Generation of viruses 
Replication-defective virus (HIV-1Env-GFP/VSVG) was generated using 
calcium-phosphate-mediated transfection of HEK293T cells. Briefly, HIV-1Env-GFP 
and VSVG plasmids were co-transfected for 6 hours. Transfection media was removed 
and cells were cultured over 2 days, with virus-containing supernatants removed at 24 
and 48 hours posttransfection. These viruses contain a frameshift mutation in envelope 
and are capable of only a single-round infection when Env is provided in trans as 
previously described [14]. Replication-competent virus (HIV-1-BAL-HSA) was 
generated through a similar transfection protocol using a single plasmid (pNL-43-BAL-
IRES-HSA) courtesy of Dr. Michel Tremblay (Centre Hospitalier de l'Université Laval). 
All viruses were quantified using p24 ELISA (Zeptometrix) and stored at -80° Celsius 
until further use. 
 
RNAseq analysis for ISGs 
MDM were generated as described and stimulated with 25ng/mL of the indicated 
IFNs. Total RNA was isolated 18 hours following stimulation using RNeasy Mini Kit 
(Qiagen). Intact poly(A) RNA was purified from total RNA samples (100-500 ng) with 
oligo(dT) magnetic beads and stranded mRNA sequencing libraries were prepared as 
described using the Illumina TruSeq Stranded mRNA Library Preparation Kit (RS-122-
2101, RS-122-2102). Purified libraries were qualified on an Agilent Technologies 2200 
TapeStation using a D1000 ScreenTape assay (cat# 5067-5582 and 5067-5583). The 
molarity of adapter-modified molecules was defined by quantitative PCR using the Kapa 
Biosystems Kapa Library Quant Kit (cat#KK4824). Individual libraries were normalized 
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to 10 nM and equal volumes were pooled in preparation for Illumina sequence analysis. 
Sequencing libraries (25 pM) were chemically denatured and applied to an Illumina 
HiSeq v4 single read flow cell using an Illumina cBot. Hybridized molecules were 
clonally amplified and annealed to sequencing primers with reagents from an Illumina 
HiSeq SR Cluster Kit v4-cBot (GD-401-4001). Following transfer of the flowcell to an 
Illumina HiSeq 2500 instrument (HCSv2.2.38 and RTA v1.18.61), a 50 cycle single-read 
sequence run was performed using HiSeq SBS Kit v4 sequencing reagents (FC-401-
4002). 
 
Discussion and perspectives 
 The field of HIV-1 biology has largely focused on the contribution of CD4+ T 
cells to host-pathogen interactions and, rightfully, on their importance to viral persistence 
and latency [14, 15]. While myeloid cells have long been recognized as an important 
target cell of HIV-1, the knowledge base related to infection of macrophages and 
dendritic cells remains comparatively sparse [16]. Much of this lack of insight is due to 
valid questions surrounding the in vivo role of macrophages [16]. Despite their 
ubiquitous presence in tissue sites important for HIV-1/AIDS pathogenesis, it is still 
unknown whether macrophages are capable of supporting a true state of latency, and 
whether they constitute a bona fide viral reservoir in vivo [17]. However, their role as 
motivators of pathogenic inflammatory responses in HIV-1/AIDS and as major targets of 
virus at transmission at mucosal sites warrants a deeper understanding of the complex 
relationship between myeloid cells and HIV-1 [2].  
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 The ability of cells to sense HIV-1 constitutes a major component of innate 
immune responses, and is postulated to affect virus seeding at mucosal sites of 
transmission [18]. The inability of macrophages to respond to virus challenge by 
mounting a robust IFN response is an important area of future investigation, one that may 
provide a more complete picture of the mechanisms of transmission and point toward 
strategies to combat HIV-1. Understanding how macrophages respond to systemic HIV-1 
infection by inducing proinflammatory responses, and whether those responses protect 
immune cells from subsequent infection, will be important in identifying pathways that 
may be targeted therapeutically to curb pathologies associated with ongoing virus 
replication and persistent inflammation.  
 Whether SAMHD1 activation is required for macrophage protection from 
subsequent challenge is an outstanding question. We will address this question through 
two major approaches: first, by identification of the viral PAMP required to trigger 
SAMHD1 activation, and second, through elimination of SAMHD1 prior to secondary 
infection. Preliminary experiments involving VSVG-pseudotyped HIV-1 particles 
suggest that the crucial recognition events for SAMHD1 activation occur independent of 
virus entry (Figure 4.1). Thus, efforts should be focused on nucleic acid components 
through inhibition of reverse transcription (to study RNA) or integration (to study DNA) 
to examine which, if any, nucleic acids are involved. By preventing recognition of the 
viral PAMP required for SAMHD1 dephosphorylation following infection, either through 
siRNA-mediated knockdown of sensors specific for recognition of RNA (RIG-I) or DNA 
(cGAS/STING), we hypothesize that subsequent infection with HIV-1 will be de-
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restricted. A similar phenotype is expected through elimination of SAMHD1 using 
Vpx(+)VLPs or siRNA targeting SAMHD1.  
 It is clear that HIV-1 induces a response in MDM that resembles IFN-induced 
ISG stimulation. However, the induction of ISGs, particularly those with anti-HIV-1 
activity, is largely blunted. A major question in the field remains regarding the 
mechanisms by which HIV-1 subverts innate immune responses. Indeed, a number of 
HIV-1 accessory proteins have been implicated in contributing to circumventing innate 
immune sensing. While these accessory proteins undoubtedly contribute to the blunted 
innate response to HIV-1, there are likely multiple mechanisms involved [19]. An 
intriguing possibility is the induction of noncoding RNAs by HIV-1, specifically those 
that act to dampen the IFN response to infection. We have shown that HIV-1 itself can 
induce the expression of a long noncoding RNA (lncRNA) in MDM, lncRNA-CMPK2. 
lncRNA-CMPK2, or Negative Regulator of Interferon Responses (NRIR), has been 
previously reported to be enriched in chronic hepatitis C virus (HCV) infected individuals 
[20]. This lncRNA also represses expression of ISGs in the context of type I IFN 
stimulation, and may be an additional mechanism by which HIV-1 counteracts the innate 
immune response [20]. Experiments aimed at elucidating the role of HIV-1-induced 
NRIR, including shRNA-mediated knockdown, are ongoing.  
The experiments included in this dissertation demonstrate that SAMHD1 
dephosphorylation at threonine-592 represents a central mechanism of HIV-1 restriction 
common to diverse families of IFNs. The finding that diverse IFNs are functional to the 
degree to which they modulate SAMHD1 phosphorylation and activation without 
effecting changes in total protein is an important step in understanding innate immune 
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responses in macrophages. We further show that use of FDA-approved TKIs leads to 
HIV-1 inhibition, and that this is dependent on the activation of SAMHD1, providing 
important mechanistic understanding as to how these compounds act and can be directed 
towards HIV-1 cure efforts.  Whether sex-dependent differences are a result of 
differential baseline expression of IFN will be the subject of future investigation, though 
precedent has been set for sex-based differences in innate immune responses in other cell 
types[8].  
The activity of SAMHD1 is regulated in a cell cycle-dependent manner, but can 
also be regulated independent of cell division, as reported in this dissertation [21]. It is 
striking that cell-cycle regulatory elements that could be viewed as dispensable in 
terminally-differentiated MDM are both present and critical in regulating SAMHD1 
phosphorylation in response to IFN stimulation and HIV-1 infection. Our results reveal 
that IFN-induced activation of SAMHD1 is effected via downregulation of CDK1 mRNA 
and suggest that in the absence of stimulation, CDK1 maintains SAMHD1 
phosphorylated and, to a large extent, inactive.  
SAMHD1 is thought to play a role in controlling cell cycle of tumor cells, where 
its activity as a triphosphohydrolase can restrain uncontrolled cellular proliferation by 
blunting cellular DNA synthesis [22]. We show that SAMHD1 activity can be targeted by 
several FDA-approved anticancer TKIs. TKIs exerted their anti-HIV-1 activity through 
SAMHD1-T592 dephosphorylation, revealing two possibilities regarding their activity. It 
will be important to understand whether the anti-HIV-1 activity of TKIs results from 
direct inhibition of CDKs known to phosphorylate SAMHD1, or whether kinase cascades 
affected by TKIs converge on CDKs to maintain steady-state levels of SAMHD1 
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phosphorylation and inactivity. The results of our inhibitor studies, using TKIs known to 
target receptor tyrosine kinases (RTK), would suggest that signaling events originating at 
the cell surface may be crucial determinants of SAMHD1 dynamics in macrophages. 
Targeting the relevant pathways may prove useful in anti-HIV-1 efforts or in preventing 
end-organ damage observed in patients on ART, including HIV-1 associated neurologic 
dysfunction. An understanding of the fundamental mechanisms may further be translated 
to the field of oncology [22].  
Macrophages are important targets of HIV-1 infection in vivo, and their 
significance to infection establishment and viral persistence is only beginning to be 
understood. It has been speculated that macrophages can support HIV-1 infection and 
harbor virus over prolonged periods of time independent of T cells, even in the setting of 
ART, a hypothesis that has recently been strengthened by experiments conducted in 
humanized myeloid-only mice. Therefore, strategies that aim to prevent virus spread to 
tissue macrophages, either independently or in the context of latency reversal strategies, 
will be important components of ongoing HIV-1 cure efforts. Understanding the 
fundamental pathways important for HIV-1 restriction, HIV-1 sensing, and innate 
immune responses will be crucial to the success of these ongoing efforts. Understanding 
the cellular and molecular determinants of sex-based differences will be crucial 
components of understanding the observed sex-dependent differences of HIV-1 infection 








Figure 4.1. HIV-1 infection leads to SAMHD1 activation and protects macrophages 
from subsequent challenge. (A) Representative flow plots of MDM infected with HIV-
1Env-GFP/VSVG or HIV-1-BAL-HSA, incubated for 48 hours, then challenged with 
HIV-1Env-mCherry/VSVG. (B) Western Blot analysis of MDM cell lysates from two 
donors (A001 and A010) in the presence or absence of HIV-1Env-GFP/VSVG. (C) 
Analysis of Western Blot via densitometry of five donors +/- HIV-1Env-GFP/VSVG. 
(D) Analysis of secondary infection of MDM with HIV-1Env-mCherry/VSVG 
following primary challenge with HIV-1Env-GFP/VSVG or  HIV-1-BAL-HSA. Values 








Figure 4.2. Conditioned media from infected macrophages fails to induce potent 
anti-HIV-1 activity in ‘bystander’ MDM. (A) Analysis of HIV-1Env-mCherry/VSVG 
infection in four donor (A009, A055, A056, A057) MDM infected following culture for 
24 hours in media derived from mock-infected macrophages (black) or macrophages 
infected with HIV-1Env-GFP/VSVG (red). (B) Summary of % infectivity in MDM 
treated with HIV-1Env-GFP/VSVG-conditioned media. Values represent infection 












Figure 4.3. Exogenous cGAMP leads to HIV-1 restriction in MDM. Analysis of % 
infected macrophages following treatment with cGAMP (1micromolar, orange; 



























Figure 4.4. STRING protein-protein interaction map from phosphoproteomic hits. 
Genes identified as differentially expressed by phosphoproteomic analysis in HIV-1-




Figure 4.5. RNAseq analysis of 83 genes differentially regulated in all comparisons. 
rlog differences were hierarchically clustered, and values in the heatmap represent the 








Figure 4.6. Comparison of type I, II, and III ISGs and HIV-1-infected MDM. (A) 
Comparison of RNAseq signatures exhibiting a log2 fold-change +2.0 or greater. (B) 
Comparison of RNAseq signatures exhibiting a log2 fold-change -2.0 or less. (C) 
Pathway analysis to determine positive (red) and negative (blue) enrichment of gene sets 
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TISSUE CULTURE METHODS FOR INVESTIGATING  
















Isolation of CD14+ monocytes from peripheral blood 
1. In a sterile fume hood, prepare two 60mL syringes (BD, Catalog #309653) for 
peripheral phlebotomy by drawing 5mL ACD Formula A (Boston Bio Products, 
Catalog #IBB-400) into each syringe.  
2. Cap each tube with syringe tip caps (BD, catalog #305819). 
3. In a sterile fume hood, prepare four 50mL conical centrifuge tubes (Fisher 
Scientific, catalog #14-432-22 or similar) for peripheral blood mononuclear cell 
(PBMC) isolation by dispensing 15mL Lymphoprep density gradient medium 
(Stemcell Technologies, catalog #07581). Prepare two tubes for each 60mL 
syringe of whole blood drawn.  
4. Take 60mL capped syringes to the phlebotomy station and perform healthy donor 
venous blood draw, filling as few as two syringes (120mL total) or as many as 
three syringes (180mL total) depending on cell quantities required. Note: isolation 
of PBMC from 120mL of whole blood and subsequent CD14+ cell isolation will 
yield, on average, 20-40 million monocytes; isolation of PBMC from 180mL of 
whole blood and subsequent CD14+ cell isolation will yield, on average, 30-50 
million monocytes. Cell counts vary widely based on the specific donor used. 
5. Working quickly, take whole blood into a sterile fume hood and slowly dispense 
30mL of whole blood directly from the BD syringe into each centrifuge tube, 
without dilution, prepared in Step 3. Note: allowing blood to sit for long periods 
of time, even with rocking at room temperature, will result in a diffuse PBMC 
layer following centrifugation over density gradient.  
6. Cap tubes containing Lymphoprep + whole blood. Balance tubes and place in 
 99 
centrifuge, spinning at 1500rpm for 30 minutes at room temperature with 
‘acceleration’ and ‘deceleration’ both set to 0 (~23-25 degrees Celsius). Note: use 
of centrifuge brake will result in mixing of PBMC layer.  
7. Remove tubes from centrifuge. A distinct buffy coat (white cell layer) will be 
obvious under a clear layer of plasma. Remove 5-10mL of the plasma layer via 
aspiration, careful not to disrupt the PBMC buffy coat resting atop a layer of 
Lymphoprep. 
8. Remove the buffy coat layer containing PBMCs and pipette into fresh 50mL 
conical tubes. Multiple tubes may be required.  
9. Wash PBMCs with 1X PBS to generate a white cell pellet. Aspirate the 
supernatant without disturbing the pellet.  
10. Resuspend PBMCs and transfer to a single 50mL conical centrifuge tube. Fill 
tube to 50mL total volume using MACS isolation buffer (1X PBS pH 7.2 with 
0.5% Bovine Serum Albumin (BSA) and 2mM EDTA).  
11. Remove a 10uL aliquot from the 50mL cell suspension and count. 
12. Resuspend PBMCs in the appropriate volume of MACS isolation buffer, 
according to the manufacturer’s recommendation (Miltenyi Biotec, catalog #130-
050-201). Note: use 8uL of buffer per 1 million cells. 
13. Add the appropriate volume of CD14+ magnetic beads, according to the 
manufacturer’s recommendation (Miltenyi Biotec, catalog #130-050-201). Note: 
use 2uL of beads per 1 million cells.  
14. Place cell suspension + beads at 4 degress Celsius for 15 minutes. 
15. Wash cells in 10mL MACS isolation buffer from Step 10. 
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16. Isolate CD14+ cells using either the AutoMACS (program: Possel_s) or MACS 
LS Columns (Miltenyi Biotec, catalog #130-042-401).  
17. Collect the CD14+ (positive) fraction, resuspend in 15mL Serum Free Media 
(SFM, RPMI 1640 supplemented with penicillin/streptomycin and L-glutamine). 
Note: DO NOT USE SERUM-CONTAINING MEDIUM AS THIS INTERFERES 
WITH EFFICIENT CELL ADHERENCE. 
18. Remove a 10uL aliquot and count cells twice to ensure accurate measurements. 
Spin down CD14+ fraction and resuspend at a final concentration of 1 million 
cells per mL. This may require transfer to a 50mL conical centrifuge tube, 
depending on cell counts. Note: DO NOT USE SERUM-CONTAINING MEDIUM 
AS THIS INTERFERES WITH EFFICIENT CELL ADHERENCE. 
19. Vigorously resuspend the cell pellet with a 1000uL pipette. Add SFM and vortex 
vigorously for 30 seconds in 5-10-second intervals. Note: Monocytes will adhere 
to each other and to plastic if left stagnant for prolonged periods of time.  
20. Plate the monocytes (resuspended in SFM) by pipetting 600uL (600,000 
cells/well, 24-well plates), 1200uL (1.2 million cells/well, 12-well plates), or 
2400uL (2.4 million cells/well, 6-well plates) of cell suspension directly into each 
well. Swirl plates to ensure even cell distribution.  
21. Place cells in an incubator for 2 hours to allow proper adherence. Note: Cells will 
begin to flatten as they adhere and will refract light differently. This step is 
important, as adding macrophage medium (serum-containing) too early will 
encourage detachment from the plate.  
22. Once cells are adhering, generate macrophage growth medium in 50mL conical 
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centrifuge tubes by supplementing SFM from Step 17 with 12% pooled human 
serum (Innovative Research, catalog #IPLA-SER). Note: Do not prepare 
macrophage growth medium in quantities exceeding 50mL, and always freeze 
down pooled human serum in 15mL aliquots for long-term storage. 
23. Following monocyte attachment, replace SFM with 600uL macrophage growth 
medium prepared in Step 22. Do not culture in any volume less than 600uL (24-
well plates). Scale up accordingly for larger plates. Note: DO NOT ASPIRATE 
SUPERNATANT FROM PLATES AS THIS WILL CAUSE THE CELLS TO 
DESSICATE. Gently pipette medium away by tilting the plate forward and 
placing the tip of the 1000uL pipette at the corner of the well. Work quickly and 
only replace media in 6 wells at a time to prevent desiccation.   
 
Culture and generation of monocyte-derived macrophages (MDM)  
1. Following CD14+ isolation, plating, and media change to macrophage growth 
medium, place plated monocytes in an incubator for 5 days. Monitor macrophage 
differentiation, noting any overt detachment or plating inconsistencies. Note: Cell 
confluency will affect downstream applications and yield inconsistent results if 
there is overt well-to-well variation. 
2. Carefully replace medium with fresh macrophage growth medium on day 5, being 
certain not to disturb the cell monolayer or allowing cells to dessicate.  
3. On day 6-7, macrophages are ready for downstream applications including 
inhibitor studies and infection. 
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Generation of env-deleted HIV-1 stocks 
1. Plate HEK293 FT cells in T-175 tissue culture flasks (Thermo Fisher, catalog 
#159910 or similar). Add 22mL DMEM supplemented with 
penicillin/streptomycin, L-glutamine, and 10% Fetal Bovine Serum (FBS).  
2. Cells are ready to transfect when they have reached 70-80% confluency. Replace 
media with prewarmed complete DMEM 2 hours prior to transfection. Note: 
Using prewarmed media will prevent cell detachment.  
3. For each plate, calculate the amount of plasmid required for 20g of viral vector 
(HIV-−Env-GFP or HIV-−Env-mCherry) and 5g of envelope (VSVG).  
4. For each plate, mix 20g of viral vector and 5g of envelope in 900uL ddH2O.  
5. After diluting the plasmids, add 22L of Chloroquine to each plate and mix 
gently.  
6. Add 100L of CaCl2 to the 900L diluted plasmid mix and mix by gentle 
pipetting.  
7. Quickly add 1000L of 2X HBS (Fisher Scientific, catalog #AAJ62623AK) to 
the diluted plasmid + CaCl2 solution and mix thoroughly by pipetting. You will 
have a final volume of 2mL of precipitated plasmid solution for each plate.  
8. Allow the mixture to rest at room temperature for 1 minute.  
9. Gently pipette 2mL of the precipitated plasmid solution from Step 7 into each 
plate. Scale up accordingly for transfection of multiple plates.  
10. Gently rock the plate containing 22mL media + Chloroquine + precipitated 
plasmid solution. Note: Precipitated DNA should be visible by light microscopy 
and generally predicts a successful transfection.  
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11. Place in the incubator and allow transfection to proceed for 6-8 hours. Note: 
Overnight transfection may enhance transfection efficiency but may lead to 
cytotoxicity.  
12. Following 6-8 hour transfection, gently remove media and replace with fresh, pre-
warmed DMEM.  
13. For VSVG-pseudotyped viruses, collection can begin as early as 12 hours 
following completion of Step 12. Typically, viruses are collected at 24 and 48 
hours posttransfection, or until cells become detached and appear dead.  
14. Combine virus supernatants collected at 24 and 48 hours posttransfection and 
DNase (Sigma Aldrich, catalog #D5025) treat for 1 hour at 37 degrees Celsius to 
remove contaminating DNA plasmid. Note: This step is optional for most 
applications but required for experiments involving PCR reactions relevant to the 
study of HIV-1.  
15. Optional: Concentrate VSVG pseudotyped virus by ultracentrifugation for 2 hours 
at 25,000rpm. Note: This is not required for macrophage infection as virus stocks 
produced using this protocol are sufficiently concentrated to generate maximum 
baseline infection in macrophages.  
16. Aliquot virus stocks in Cryovials (Corning, catalog #09-761-71) for storage at -80 
degrees Celsius, saving 50L for p24 determination via ELISA (ZeptoMetrix, 
catalog #0801111). Note: It is best to save multiple virus supernatants to run a 




Generation of replication-competent HIV-1 stocks 
1. Plate HEK293 FT cells in T-175 tissue culture flasks (Thermo Fisher, catalog 
#159910 or similar). Add 22mL DMEM supplemented with 
penicillin/streptomycin, L-glutamine, and 10% Fetal Bovine Serum (FBS).  
2. Cells are ready to transfect when they have reached 70-80% confluency. Replace 
media with prewarmed complete DMEM 2 hours prior to transfection. Note: 
Using prewarmed media will prevent cell detachment.  
3. For each plate, calculate the amount of plasmid required for 25g of viral vector 
(HIV-1-NL-4-3-AD8 or HIV-1-NL-4-3-BaL-IRES-HSA). 
4. For each plate, dilute 25g viral vector in 900uL ddH2O. Note: HIV-1-NL-4-3-
AD8 and HIV-1-NL-4-3-BaL-IRES-HSA maintain envelope intact and thus do not 
require complementation with an envelope-encoding plasmid.  
5. After diluting the plasmids, add 22L of Chloroquine to each plate and mix 
gently.  
6. Add 100L of CaCl2 to the 900L diluted plasmid mix and mix by gentle 
pipetting.  
7. Quickly add 1000L of 2X HBS (Fisher Scientific, catalog #AAJ62623AK) to 
the diluted plasmid + CaCl2 solution and mix thoroughly by pipetting. You will 
have a final volume of 2mL of precipitated plasmid solution for each plate.  
8. Allow the mixture to rest at room temperature for 1 minute.  
9. Gently pipette 2mL of the precipitated plasmid solution from Step 7 into each 
plate. Scale up accordingly for transfection of multiple plates.  
10. Gently rock the plate containing 22mL media + Chloroquine + precipitated 
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plasmid solution. Note: Precipitated DNA should be visible by light microscopy 
and generally predicts a successful transfection.  
11. Place in the incubator and allow transfection to proceed for 6-8 hours. Note: 
Overnight transfection may enhance transfection efficiency but may lead to 
cytotoxicity.  
12. Following 6-8-hour transfection, gently remove media and replace with fresh, pre-
warmed DMEM.  
13. Collect viral supernatants at 24 and 48 hours posttransfection, or until cells 
become detached and appear dead.  
14. Combine virus supernatants collected at 24 and 48 hours posttransfection and 
DNase (Sigma Aldrich, catalog #D5025) treat for 1 hour at 37 degrees Celsius to 
remove contaminating DNA plasmid. Note: This step is optional for most 
applications but required for experiments involving PCR reactions relevant to the 
study of HIV-1.  
15. Aliquot virus stocks in Cryovials (Corning, catalog #09-761-71) for storage at -80 
degrees Celsius, saving 50L for p24 determination via ELISA (ZeptoMetrix, 
catalog #0801111). Note: It is best to save multiple virus supernatants to run a 
single p24 ELISA.  
 
Infection of MDM in static culture 
1. Culture macrophages for 7 days according to the protocol described in “Culture 
and Generation of Monocyte-Derived Macrophages (MDM) from Healthy Donor 
CD14+ Monocytes.”  
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2. On day 7, thaw virus from Cryovials at room temperature. Calculate the volume 
of viral supernatants equivalent to 500ng of p24 as determined by ELISA in 
“Generation of HIV-1-NL-4-3-AD8 and HIV-1-NL-4-3-BaL-IRES-HSA virus 
stocks for infection of MDM in static culture.” 
3. Mix the appropriate amount of virus with macrophage growth medium such that 
each infection contains 500ng of p24 in a 250L total final volume.  
4. Gently remove macrophage growth media from each well using a 1000L pipette 
by tilting the plate and pipetting. Work quickly and refrain from pulling media 
from more than 6 wells at a time to prevent desiccation.  
5. Gently pipette the 250L virus mixture against the side wall of each individual 
well, allowing the solution to cascade gently over the cells. Note: Do not pipette 
the virus solution directly onto the macrophage monolayer, as disturbances can 
vastly affect the viability, infectivity, and behavior of MDM.  
6. Place the culture plates back in the incubator for 4-6 hours to allow infection to 
proceed. Note: DO NOT leave macrophages in low-volume (250L) culture 
overnight. Evaporation will occur and expose macrophages to desiccation.  
7. Gently remove virus supernatant following 4-6-hour incubation, wash once with 
250L macrophage growth medium to remove any unbound virus, and replace 
with 600L fresh macrophage growth medium. Analyze 48 hours later.  
 
Analysis of MDM infection 
1. Remove medium 48 hours postinfection and replace with 400L Gibco StemPro 
Accutase Cell Dissociation Reagent (Fisher Scientific, catalog #A1110501). 
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Allow macrophages to detach in Accutase for 2-3 hours. Depending on 
confluency and cell density, detachment may take as long as 4 hours. Note: Cells 
will require gentle washing to aid in detachment. This is best accomplished by 
gently taking up Accutase using the 1000L pipette and slowly washing around 
each well until the majority of cells are in suspension. 
2. Once cells are detached, place in tubes suitable for flow cytometry and wash with 
1 volume 1X PBS.  
3. Prior to staining for analysis of cell surface markers, Fc receptors present on 
macrophages must be blocked using FcR Blocking Reagent, Human (Miltenyi 
Biotec, catalog #130-059-901) and stained for viability using eBioscience Fixable 
Viability Dye eFluor450 (Fisher Scientific, catalog #65-0863-14). For each test, 
dilute 0.5L of Viability Dye and 2L of FcR Blocking Reagent in 100L of 1X 
PBS. Incubate at 4 degrees Celsius for 30 minutes.  
4. Stain for any pertinent cell surface markers according to the manufacturer’s 
protocol. Wash unbound antibody before proceeding to Step 5. Note: Accutase 
treatment may prevent detection of certain epitopes by flow cytometry – refer to 
the manufacturer for details.  
5. For infection with HIV-−Env-GFP/VSVG and HIV-−Env-mCherry/VSVG, 
fix cells using BD Cytofix (Becton Dickinson, catalog #554714) according the 
manufacturer’s protocol. For infection with HIV-1-NL-4-3-AD8 or HIV-1-NL-4-
3-BaL-IRES-HSA, proceed to Step 7.  
6. Wash cells by adding 1mL 1X PBS. Aspirate all but 200L of the wash solution. 
Cells are now ready for flow cytometry.  
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7. Fix and permeabilize cells from Step 4 using BD Cytofix/Cytoperm (Becton 
Dickinson, catalog #554722) according to the manufacturer’s protocol.  
8. Dilute BD Perm/Wash (Becton Dickinson, catalog #554723) according to the 
manufacturer’s protocol.  
9. Wash cells using BD Perm/Wash according to the manufacturer’s protocol.  
10. For each test, dilute 1L of anti-HIV-1 core antigen, KC57 (Fisher Scientific, 
catalog #CO6604665) in 100L diluted BD Perm/Wash solution. Allow p24 stain 
to proceed for 30 minutes at 4 degrees Celsius, protected from light. Note: You 
must use BD Perm/Wash to maintain permeabilization during the intracellular 
staining process.  
11. After 30 minutes, wash cells in 1X BD Perm/Wash, aspirating all but 200L 
following centrifugation. Cells are ready for flow cytometry. 
 
Whole cell lysate extraction and Western Blot analysis 
1. Culture macrophages for 6-7 days according to the protocol described in “Culture 
and Generation of Monocyte-Derived Macrophages (MDM) from Healthy Donor 
CD14+ Monocytes.”  
2. Prepare 10mL of NETN containing one tablet each cOmplete ULTRA EDTA-
Free Protease Inhibitor Cocktail Tablet, mini (Sigma Aldrich, catalog 
#5892953001) and PhosSTOP (Sigma Aldrich, catalog #4906845001). Mix 
thoroughly at room temperature until tablets have completely dissolved, then 
aliquot into 1.5mL Eppendorf tubes and freeze at -20 degrees Celsius.  
3. Remove macrophage growth medium from each well and wash cells with 500L 
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1X PBS. While NETN is cold, add 100L per well and rock the plate to ensure all 
cells are covered.  
4. Allow lysis to occur for 1 minute, then using the 200L pipette, begin to wash the 
cells/cell debris off the bottom of the well.  
5. Once all cells have been released from the well, place the NETN cell lysate in a 
fresh 1.5mL Eppendorf and place on ice for 30 minutes.  
6. Take lysates on ice to a sonicator bath and pulse lysates once for 15 seconds to 
shear DNA and clarify extracts. Note: Allowing lysates to warm to room temp or 
longer sonication will affect quality of Western Blots, specifically when probing 
for phosphoproteins.  
7. After sonication, spin lysates to pellet cell debris. Carefully remove the aqueous 
layer and place in a fresh 1.5mL Eppendorf. Label Eppendorf with donor ID, cell 
type, any experimental conditions used, and the date.  
8. Place extracts at -20 degrees Celsius for long-term storage or proceed to Step 8 
for quantification by BCA.  
9. Dilute extracts 1:10 in NETN, generating a 60L final volume. Note: You do 
NOT need to use NETN supplemented with PhosSTOP and cOmplete Protease 
Inhibitor Cocktail for protein quantification by BCA.  
10. Following the manufacturer’s protocol, perform the Pierce BCA Protein Assay 
using the diluted cell extracts from Step 9 (Thermo Fisher, catalog #23225).  
11. Incubate for 30 minutes at 37 degrees Celsius. After 30 minutes, allow the plate to 
cool to room temperature prior to analyzing on the plate reader. 
12. Read the absorbance on the plate reader with the spectrophotometer set to 562nm.  
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13. Calculate the final concentration of the extracts by multiplying the value read on 
the plate reader by 10.  
14. For Western Blots, calculate the volume required for 12.5g of protein. Dilute to 
25L in NETN containing PhosSTOP and cOmplete ULTRA tablets. Note: It is 
crucial to dilute in NETN with phosphatase and protease inhibitors at this step.  
15. Add 4.2L 6X Lamelli Buffer and boil at 100 degrees Celsius for 10 minutes. 
Note: Use lid locks to prevent caps from opening during boiling.  
16. Spin 1.5mL Eppendorf tubes down to collect the 29.2L final total volume.  
17. Pipette 26L of the protein/Lamelli Buffer mixture into each well of the precast 
Western Blot gel.  
18. Allow electrophoresis to run at 70-90V until the dye has run to the end of the gel. 
Note: Running at lower voltage prevents irregularities (‘smiles’) in the gel.  
19. While the gel is running, prepare a section of membrane cut to mirror the size and 
shape of the blot paper (Bio-Rad, catalog #1703932). 
20. Activate the membrane by rocking in pure Methanol for 5-10 minutes.  
21. Prepare a solution containing 10mL 10X Transfer Buffer, 20mL Methanol, and 
70mL ddH2O (total volume = 100mL) for each gel run. Place the membrane in 
this solution and rock for 20-30 minutes to equilibrate the membrane.  
22. As the gel is nearing its end point, soak a piece of blot paper in the transfer buffer 
solution from Step 21 and place on the transfer station. Roll the blot paper firmly 
enough to remove air bubbles, but be careful not to squeeze all of the transfer 
solution out.  
23. When gel has finished running, remove from electrophoresis tank and quickly 
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rinse in water.  
24. Take gel to the transfer station and crack the sides of the gel casing and remove 
the top portion. Note: You must work quickly to prevent the gel from desiccating 
and to maintain the appropriate moisture content on the blot paper to ensure 
efficient protein transfer.  
25. Remove the membrane from the transfer buffer from Step 21 and gently place on 
the wet blot paper. Pour a small amount of the transfer solution on top of the 
membrane to ensure it does not dry out.  
26. With a small amount of pressure, roll any air bubbles out from between the blot 
paper and the membrane.  
27. Working quickly, place the gel on the membrane by handling at the thickest part 
of the gel (the bottom). Do your best to ensure there are no large air bubbles 
underneath the gel. 
28. Soak another piece of blot paper in the transfer buffer solution and quickly place 
atop the gel. Roll the entire sandwich to ensure all air bubbles are removed and 
the blot paper is snug against the gel.  
29. Set the transfer station to run at 20V, 0.4A, for 30 minutes. 
30. Once the transfer is complete, place the membrane in 4% BSA (prepared in 
TPBS, NOT water) and block for at least 1 hour.  
31. Cut the membrane after blocking into the desired sections and incubate overnight, 
rocking at 4 degrees C with the desired primary antibody diluted according to the 
manufacturer’s instructions.  
32. The next day, remove the primary antibody and wash 3X for 5 minutes in TPBS.  
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33. Add the secondary antibody, diluted in 4% BSA, and incubate rocking for at least 
2 hours at room temperature. Note: Actin is ready to be developed after 30 
minutes of rocking with the secondary antibody. 
34. Wash the membranes 3X for 5 minutes in TPBS.  
35. Develop each membrane individually by rocking for 3.5 minutes in SuperSignal 
West Pico PLUS Substrate (Thermo Fisher, catalog #345850).  
 
Generation of Vpx-VLPs and degradation of SAMHD1 
1. Plate HEK293 FT cells in T-175 tissue culture flasks (Thermo Fisher, catalog 
#159910 or similar). Add 22mL DMEM supplemented with 
penicillin/streptomycin, L-glutamine, and 10% Fetal Bovine Serum (FBS).  
2. Cells are ready to transfect when they have reached 70-80% confluency. Replace 
media with prewarmed complete DMEM 2 hours prior to transfection. Note: 
Using prewarmed media will prevent cell detachment.  
3. For each plate, calculate the amount of plasmid required for 20g of viral vector 
(SIV3+ for Vpx(+)VLPs or SIV3+Vpx for control Vpx(-)VLPs) and 5g of 
envelope (VSVG).  
4. For each plate, mix 20g of viral vector and 5g of envelope in 900uL ddH2O.  
5. After diluting the plasmids, add 22L of Chloroquine to each plate and mix 
gently.  
6. Add 100L of CaCl2 to the 900L diluted plasmid mix and mix by gentle 
pipetting.  
7. Quickly add 1000L of 2X HBS (Fisher Scientific, catalog #AAJ62623AK) to 
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the diluted plasmid + CaCl2 solution and mix thoroughly by pipetting. You will 
have a final volume of 2mL of precipitated plasmid solution for each plate.  
8. Allow the mixture to rest at room temperature for 1 minute.  
9. Gently pipette 2mL of the precipitated plasmid solution from Step 7 into each 
plate. Scale up accordingly for transfection of multiple plates.  
10. Gently rock the plate containing 22mL media + Chloroquine + precipitated 
plasmid solution. Note: Precipitated DNA should be visible by light microscopy 
and generally predicts a successful transfection.  
11. Place in the incubator and allow transfection to proceed for 6-8 hours. Note: 
Overnight transfection may enhance transfection efficiency but may lead to 
cytotoxicity.  
12. Following 6-8-hour transfection, gently remove media and replace with fresh, pre-
warmed DMEM.  
13. For VSVG-pseudotyped VLPs, collection can begin as early as 12 hours 
following completion of Step 12. Typically, viruses are collected at 24 and 48 
hours posttransfection, or until cells become detached and appear dead.  
14. Combine virus supernatants collected at 24 and 48 hours posttransfection and 
DNase (Sigma Aldrich, catalog #D5025) treat for 1 hour at 37 degrees Celsius to 
remove contaminating DNA plasmid. Note: This step is optional for most 
applications but required for experiments involving PCR reactions relevant to the 
study of HIV-1. 
15. Concentrate VSVG pseudotyped VLPs by ultracentrifugation for 2 hours at 
25,000rpm.  
 114 
16. Aspirate the supernatant down to 2-3mL, careful not to remove any of the pelleted 
VLPs. Resuspend the pellets by gentle pipetting in a total volume of 5mL per 
tube. 
17. Combine each resuspension and aliquot virus stocks in Cryovials (Corning, 
catalog #09-761-71) for storage at -80 degrees Celsius, saving 50L for 
ZeptoMetrix p27 determination via ELISA (Fisher Scientific, catalog #22-156-
775). Note: It is best to save multiple virus supernatants to run a single p27 
ELISA. 
 
siRNA delivery to MDM  
1. ON-TARGETplus SMARTpool siRNAs are ordered from Dharmacon and diluted 
to achieve a 20M stock. For 5nmol of siRNA, resuspend in 250L 1X siRNA 
buffer. Nanodrop to confirm concentration according to the manufacturer’s 
specifications. 
2. Aliquot siRNAs to 25L stocks to avoid repeated freeze-thaw cycles.  
3. Begin siRNA experiments when macrophages have reached day 5.  
4. Determine the number of wells required for the experiment. Note: Typically, 6 
wells will be needed – 3 for infections (triplicate) and 3 for generation of whole 
cell lysate (combined).  
5. Prewarm OptiMEM media in the 37 degree bed bath. 
6. For each well to be treated, aliquot 2.5L of the 20M stock siRNA and dilute in 
47.5L warmed OptiMEM. Note: For 6 wells, prepare 6.5 ‘reactions’. This is the 
equivalent of 16.25L stock siRNA + 308.75L OptiMEM.  
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7. For each well to be treated, aliquot 2.5L Lipofectamine RNAiMAX (Fisher 
Scientific, catalog #13778150) and dilute in 47.5L warmed OptiMEM. Note: 
For 6 wells, prepare 6.5 ‘reactions’. This is the equivalent of 16.25L 
Lipofectamine RNAiMAX + 308.75L OptiMEM (325L of diluted Lipofectamine 
for each siRNA to be used).  
8. Combine the diluted siRNA with the diluted Lipofectamine RNAiMAX for a final 
volume of 650L. This is enough siRNA for 6 wells at 100L per well. 
9. Allow the mixture to rest at room temperature for 10 minutes.  
10. After 10-minute incubation, add 900L warmed OptiMEM for a final volume of 
1550L. 
11. Aliquot 225L of the mixture from Step 10 to each well.  
12. Incubate for 6 hours at 37 degrees Celsius. Note: Longer incubation times will 
allow for evaporation, exposing cells to desiccation.  
13. After 6 hours incubation, add 225L macrophage growth medium and incubate 
overnight at 37 degrees Celsius. Note: The concentration of siRNA is now 111nM.  
14. The next morning (day 6 postdifferentiation), repeat Steps 4-13. 
15. On day 7, cells are ready for downstream applications.  
